

<rss version="2.0"
     xmlns:content="http://purl.org/rss/1.0/modules/content/"
     xmlns:wfw="http://wellformedweb.org/CommentAPI/"
     xmlns:dc="http://purl.org/dc/elements/1.1/"
     xmlns:atom="http://www.w3.org/2005/Atom"
     xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
     xmlns:slash="http://purl.org/rss/1.0/modules/slash/">

    <channel>
        <title>PharmiWeb.com Press Releases</title>
        <atom:link href="https://www.pharmiweb.com/rss/press-releases-7-days" rel="self" type="application/rss+xml" />
        <link>https://www.pharmiweb.com</link>
        <description>PharmiWeb.com | Press Releases in the Pharmaceutical industry</description>
        <lastBuildDate>Mon, 01 Jun 2026 12:19:12 +00:00</lastBuildDate>
        <language>en-GB</language>
        <sy:updatePeriod>hourly</sy:updatePeriod>
        <sy:updateFrequency>1</sy:updateFrequency>
                <item>
                <title>Will State Marijuana Operators Get a Federal Green Light Before DEA Resolves MMJ&#39;s Seven-Year Wait?</title>
                <link>https://www.pharmiweb.com/press-release/2026-05-31/will-state-marijuana-operators-get-a-federal-green-light-before-dea-resolves-mmjs-seven-year-wait</link>
                <pubDate>Sun, 31 May 2026 01:40:00 +00:00</pubDate>
                <guid isPermaLink="false">234183</guid>
                <description><![CDATA[&quot;One DEA Schedule I laboratory registration approved. FDA INDs granted. Orphan Drug Designation awarded. Yet the cultivation application remains unresolved as patients continue to wait. This is responsible drug policy?&quot; stated Duane Boise, CEO MMJ International Holdings.Anne Milgram is gone, and most of the architects of pharmaceutical obstruction have retired. As the June 29 rescheduling hearing approaches, the DEA must answer for a decade of systematic patient abandonment. WASHINGTON, D.C....]]></description>
                </item>
                <item>
                <title>MMJ ET AL PREPARES APPEAL CMS HEMP PROGRAM: How Can a Company With a Manufactured Pharmaceutical Soft Gel Be Told It Has &quot;No Product&quot;?</title>
                <link>https://www.pharmiweb.com/press-release/2026-05-30/mmj-et-al-prepares-appeal-cms-hemp-program-how-can-a-company-with-a-manufactured-pharmaceutical-sof</link>
                <pubDate>Sat, 30 May 2026 12:40:00 +00:00</pubDate>
                <guid isPermaLink="false">234180</guid>
                <description><![CDATA[JUDGE McFADDEN SAID MMJ HAS &quot;NO PRODUCT.&quot; THE RECORD SAYS OTHERWISE.How Can a Company With FDA INDs, Orphan Drug Designation, Manufactured Soft gel Capsules, and Reproducible Chemistry Be Described as Having &quot;No Product&quot;? asked Duane Boise, CEO MMJ International Holdings. WASHINGTON, D.C. / ACCESS Newswire / May 30, 2026 / One sentence from Judge Trevor McFadden&#39;s dismissal of Smart Approaches to Marijuana challenge to CMS&#39;s cannabinoid reimbursement program may ultimately become one of the m...]]></description>
                </item>
                <item>
                <title>Black Book 2026 Payer Digital Technology Survey Establishes Rigorous 18-KPI Standard for Health Plan IT Client Satisfaction Rankings</title>
                <link>https://www.pharmiweb.com/press-release/2026-05-29/black-book-2026-payer-digital-technology-survey-establishes-rigorous-18-kpi-standard-for-health-plan</link>
                <pubDate>Fri, 29 May 2026 03:30:00 +00:00</pubDate>
                <guid isPermaLink="false">234178</guid>
                <description><![CDATA[Proprietary qualitative model evaluates payer technology, managed services, BPaaS, analytics, AI, cybersecurity, interoperability, clinical operations, administrative operations, and transformation partners through verified user experience and operational evidence LAS VEGAS, NV / ACCESS Newswire / May 29, 2026 / Black Book Research&#39;s 2026 State of Payer Digital Technology: Managed Care and Health Plans report introduces an industry-centric 18-KPI client satisfaction model for evaluating payer...]]></description>
                </item>
                <item>
                <title>Dr. Ran Rubinstein Brings BioRePeel to Newburgh, NY and Montvale, NJ</title>
                <link>https://www.pharmiweb.com/press-release/2026-05-29/dr-ran-rubinstein-brings-biorepeel-to-newburgh-ny-and-montvale-nj</link>
                <pubDate>Fri, 29 May 2026 02:00:00 +00:00</pubDate>
                <guid isPermaLink="false">234177</guid>
                <description><![CDATA[Dr. Ran Rubinstein introduces BioRePeel to both New York and New Jersey practices as demand grows for no-downtime skin rejuvenation treatments. NEWBURGH, NY AND MONTVALE, NJ / ACCESS Newswire / May 29, 2026 / Dr. Ran Rubinstein, double board-certified facial plastic surgeon, has added BioRePeel to the skin rejuvenation menu at both of his practices. Patients in the Hudson Valley can now book the treatment at Laser &amp;amp; Cosmetic Surgery Specialists, PC in Newburgh, New York, and patients in n...]]></description>
                </item>
                <item>
                <title>Sunshine Biopharma Announces Issuance of U.S. Patent 12,624,066 B2 Covering Novel Coronavirus Treatment Technology</title>
                <link>https://www.pharmiweb.com/press-release/2026-05-29/sunshine-biopharma-announces-issuance-of-us-patent-12-624-066-b2-covering-novel-coronavirus-treatm</link>
                <pubDate>Fri, 29 May 2026 08:00:00 +00:00</pubDate>
                <guid isPermaLink="false">234176</guid>
                <description><![CDATA[FORT LAUDERDALE, FL / ACCESS Newswire / May 29, 2026 / Sunshine Biopharma Inc. (NASDAQ:SBFM) (the &quot;Company&quot;), a leading pharmaceutical company specializing in generic and specialty prescription medications, today announced that the United States Patent and Trademark Office has issued U.S. Patent No. 12,624,066 B2, titled &quot;Compounds and Methods for Treatment of Coronavirus Infection.&quot; The newly granted patent protects Sunshine Biopharma&#39;s proprietary therapeutic compounds designed to inhibit c...]]></description>
                </item>
                <item>
                <title>MMJ International Holdings Files Formal Challenge To DEA Marijuana Rescheduling As Constitutional, Treaty, And Pharmaceutical Questions Collide</title>
                <link>https://www.pharmiweb.com/press-release/2026-05-29/mmj-international-holdings-files-formal-challenge-to-dea-marijuana-rescheduling-as-constitutional-t</link>
                <pubDate>Fri, 29 May 2026 06:00:00 +00:00</pubDate>
                <guid isPermaLink="false">234172</guid>
                <description><![CDATA[&quot;After Eight Years, Millions invested, FDA INDs, Orphan Drug Designation, DEA Inspections, and a Completed Federal Investigation, MMJ Demands the Government Explain Why Companies That Followed Federal Law Were Left Behind&quot; asked Duane Boise, CEO MMJ International Holdings. WASHINGTON, D.C. / ACCESS Newswire / May 29, 2026 / MMJ International Holdings, (&quot;MMJ&quot;), together with its subsidiaries MMJ BioPharma Cultivation, and MMJ BioPharma Labs, announced today that it has formally entered the Dru...]]></description>
                </item>
                <item>
                <title>Hemogenyx Pharmaceuticals PLC Announces Grant of Options and Extension of Warrant Term </title>
                <link>https://www.pharmiweb.com/press-release/2026-05-29/hemogenyx-pharmaceuticals-plc-announces-grant-of-options-and-extension-of-warrant-term</link>
                <pubDate>Fri, 29 May 2026 04:50:00 +00:00</pubDate>
                <guid isPermaLink="false">234169</guid>
                <description><![CDATA[THIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION AS STIPULATED UNDER THE UK VERSION OF THE MARKET ABUSE REGULATION NO 596/2014 WHICH IS PART OF ENGLISH LAW BY VIRTUE OF THE EUROPEAN (WITHDRAWAL) ACT 2018, AS AMENDED. ON PUBLICATION OF THIS ANNOUNCEMENT VIA A REGULATORY INFORMATION SERVICE, THIS INFORMATION IS CONSIDERED TO BE IN THE PUBLIC DOMAIN.Grant of Options and Extension of Warrant Term LONDON, UK / ACCESS Newswire / May 29, 2026 / Hemogenyx Pharmaceuticals plc (LSE:HEMO), a clinical-stage...]]></description>
                </item>
                <item>
                <title>Cantargia AB to Host Webcast Covering Rights Issue, Loan Agreement, and Strategic Priorities</title>
                <link>https://www.pharmiweb.com/press-release/2026-05-28/cantargia-ab-to-host-webcast-covering-rights-issue-loan-agreement-and-strategic-priorities</link>
                <pubDate>Thu, 28 May 2026 03:35:00 +00:00</pubDate>
                <guid isPermaLink="false">234154</guid>
                <description><![CDATA[LUND, SE / ACCESS Newswire / May 28, 2026 / Cantargia (STO:CANTA) - With reference to the Company&#39;s press release on May 28, 2026, regarding the decision to conduct a rights issue in combination with a loan, Cantargia AB (Publ) (&quot;Cantargia&quot; or the &quot;Company&quot;) invites shareholders, analysts and the press to a live web cast on June 1, 2026, at 4 pm CEST with details below.&quot;This rights issue strengthens our ability to deliver on nadunolimab&#39;s full potential,&quot; said Hilde Steineger, CEO of Cantargi...]]></description>
                </item>
                <item>
                <title>The Naderi Center for Plastic Surgery Weighs In on What the Public Gets Wrong About Deep Plane Facelift Techniques and Longevity</title>
                <link>https://www.pharmiweb.com/press-release/2026-05-28/the-naderi-center-for-plastic-surgery-weighs-in-on-what-the-public-gets-wrong-about-deep-plane-facel</link>
                <pubDate>Thu, 28 May 2026 01:00:00 +00:00</pubDate>
                <guid isPermaLink="false">234153</guid>
                <description><![CDATA[Facial plastic surgeon explains how technique, tissue quality, and healing timelines influence facelift outcomes beyond social media speculation. CHEVY CHASE, MD AND WASHINGTON, DC / ACCESS Newswire / May 28, 2026 / In response to widespread online speculation surrounding celebrities and facelift procedures, Dr. Shervin Naderi, a double board-certified specialist in facial plastic surgery at The Naderi Center for Plastic Surgery, is providing his professional insight into what truly matters w...]]></description>
                </item>
                <item>
                <title>Jaguar Health Research in Ethnobotanical Medicine Helps Advance Crofelemer Development for Genetically Defined Rare Congenital Gastrointestinal Disorders</title>
                <link>https://www.pharmiweb.com/press-release/2026-05-28/jaguar-health-research-in-ethnobotanical-medicine-helps-advance-crofelemer-development-for-genetical</link>
                <pubDate>Thu, 28 May 2026 10:00:00 +00:00</pubDate>
                <guid isPermaLink="false">234148</guid>
                <description><![CDATA[Crofelemer delayed-release tablets are Jaguar&#39;s FDA-approved prescription drug under botanical guidance (&quot;botanical drug&quot;) derived from the Croton lechleri tree. Crofelemer, in a novel liquid formulation, is being developed as the potential first oral adjunctive therapy for Intestinal Failure (IF) from microvillus inclusion disease (MVID) and short bowel syndrome (SBS)Crofelemer development with novel formulations for different gastrointestinal disorders reflects a differentiated botanical dr...]]></description>
                </item>
                <item>
                <title>Will Physicians Risk Their Licenses For CMS Hemp Products The FDA Never Approved?</title>
                <link>https://www.pharmiweb.com/press-release/2026-05-28/will-physicians-risk-their-licenses-for-cms-hemp-products-the-fda-never-approved</link>
                <pubDate>Thu, 28 May 2026 09:50:00 +00:00</pubDate>
                <guid isPermaLink="false">234147</guid>
                <description><![CDATA[&quot;As SAM (Smart Approaches To Marijuana) and MMJ International Holdings Prepare an Appeal, Medicare Doctors Now Stand Between Seniors and Uncharacterized, Unsafe Hemp Products,&quot; stated Duane Boise, CEO MMJ International Holdings. WASHINGTON, D.C. / ACCESS Newswire / May 28, 2026 / Judge Trevor McFadden dismissed the challenge to CMS&#39;s Substance Access Beneficiary Engagement Incentive (BEI) program on standing grounds, ruling that no plaintiff had demonstrated a sufficiently concrete injury.But...]]></description>
                </item>
                <item>
                <title>SoCal Aesthetic Surgery Named &quot;Best of 2026&quot; by BusinessRate for Excellence in Plastic Surgery</title>
                <link>https://www.pharmiweb.com/press-release/2026-05-28/socal-aesthetic-surgery-named-best-of-2026-by-businessrate-for-excellence-in-plastic-surgery</link>
                <pubDate>Thu, 28 May 2026 10:00:00 +00:00</pubDate>
                <guid isPermaLink="false">234146</guid>
                <description><![CDATA[BusinessRate recognition reflects consistently positive patient feedback and trusted facial plastic surgery care in Irvine and throughout Orange County. IRVINE, CA / ACCESS Newswire / May 28, 2026 / SoCal Aesthetic Surgery, a facial plastic surgery practice based in Irvine, California, has been named a &quot;Best of 2026&quot; award winner by BusinessRate. The recognition highlights the practice&#39;s strong reputation among patients and its consistently positive feedback across verified online review plat...]]></description>
                </item>
                <item>
                <title>Sunshine Biopharma Announces Reverse Stock Split to Maintain NASDAQ Listing</title>
                <link>https://www.pharmiweb.com/press-release/2026-05-28/sunshine-biopharma-announces-reverse-stock-split-to-maintain-nasdaq-listing</link>
                <pubDate>Thu, 28 May 2026 09:00:00 +00:00</pubDate>
                <guid isPermaLink="false">234145</guid>
                <description><![CDATA[FORT LAUDERDALE, FL / ACCESS Newswire / May 28, 2026 / Sunshine Biopharma Inc. (NASDAQ:SBFM) (the &quot;Company&quot;), a leading pharmaceutical company specializing in generic and specialty prescription medications, today announced a one for ten reverse split of its common stock, effective at market open on June 1, 2026. The reverse stock split was undertaken to regain compliance with Nasdaq&#39;s minimum bid price requirement for continued listing. The reverse stock split will reduce the Company&#39;s issued...]]></description>
                </item>
                <item>
                <title>Patient Safety Movement Foundation Appoints Three Distinguished Leaders to Governance Board</title>
                <link>https://www.pharmiweb.com/press-release/2026-05-28/patient-safety-movement-foundation-appoints-three-distinguished-leaders-to-governance-board</link>
                <pubDate>Thu, 28 May 2026 08:45:00 +00:00</pubDate>
                <guid isPermaLink="false">234144</guid>
                <description><![CDATA[Global nonprofit strengthens leadership with expertise spanning government, medicine, and international healthcare systems in pursuit of zero preventable patient harm IRVINE, CA / ACCESS Newswire / May 28, 2026 / The Patient Safety Movement Foundation (PSMF) today announced the appointment of three distinguished global leaders to its Governance Board: Rt. Hon. Sir Jeremy Hunt, MP, who served as the United Kingdom&#39;s Chancellor of the Exchequer from 2022 to 2024, and a former Minister of Health...]]></description>
                </item>
                <item>
                <title>Medical Care Technologies (OTC PINK:MDCE) Provides Additional Details Regarding MDCE Melanoma Scan Beta Imaging Platform</title>
                <link>https://www.pharmiweb.com/press-release/2026-05-28/medical-care-technologies-otc-pinkmdce-provides-additional-details-regarding-mdce-melanoma-scan-b</link>
                <pubDate>Thu, 28 May 2026 08:47:00 +00:00</pubDate>
                <guid isPermaLink="false">234143</guid>
                <description><![CDATA[Company discusses AI-assisted body-map monitoring architecture and long-term imaging technology development initiatives MESA, AZ / ACCESS Newswire / May 28, 2026 / Medical Care Technologies Inc. (OTC PINK:MDCE) (&quot;MDCE&quot; or the &quot;Company&quot;), a technology company focused on AI-powered imaging and wellness applications, today provided additional details regarding the design framework and development objectives of its MDCE Melanoma Scan Beta platform.  The beta-stage platform is being developed as a...]]></description>
                </item>
                <item>
                <title>Faron Pharmaceuticals LTD: Holding(S) In Company</title>
                <link>https://www.pharmiweb.com/press-release/2026-05-28/faron-pharmaceuticals-ltd-holding-s-in-company</link>
                <pubDate>Thu, 28 May 2026 09:15:00 +00:00</pubDate>
                <guid isPermaLink="false">234142</guid>
                <description><![CDATA[TURKU, FI / ACCESS Newswire / May 28, 2026 / Faron Pharmaceuticals (HEL:FARON)(LSE:FARN)Standard form for notification of major holdingsNOTIFICATION OF MAJOR HOLDINGS (to be sent to the relevant issuer and to the FIN-FSA) 1. Identity of the issuer:Faron Pharmaceuticals Oy2. Reason for the notification (please tick the appropriate box or boxes):☐ An acquisition or disposal of shares or voting rights☒ An acquisition or disposal of financial instruments☐ An event changing the breakdown of shares...]]></description>
                </item>
                <item>
                <title>ONS figures show fall in alcohol deaths as improved treatments take effect</title>
                <link>https://www.pharmiweb.com/press-release/2026-05-28/ons-figures-show-fall-in-alcohol-deaths-as-improved-treatments-take-effect</link>
                <pubDate>Thu, 28 May 2026 10:19:00 +00:00</pubDate>
                <guid isPermaLink="false">234133</guid>
                <description><![CDATA[A leading alcohol‑reduction specialist credits advances in moderation therapies for a decline in the number of UK alcohol‑specific deaths
 
The latest Office for National Statistics (ONS) report on alcohol‑specific deaths in the UK reveals a decline for the first time since 2018. The alcohol reduction specialists Sinclair Method UK attribute part of the decrease to the growing use and effectiveness of evidence‑based moderation treatments, as opposed to abstinence‑only methods.
The annual ONS...]]></description>
                </item>
                <item>
                <title>Creative Biogene Supports Transforming Cell Therapy with In Vivo RNA-based CAR-T Development Solutions</title>
                <link>https://www.pharmiweb.com/press-release/2026-05-28/creative-biogene-supports-transforming-cell-therapy-with-in-vivo-rna-based-car-t-development-solutions</link>
                <pubDate>Thu, 28 May 2026 09:28:38 +00:00</pubDate>
                <guid isPermaLink="false">234121</guid>
                <description><![CDATA[Creative Biogene is a dedicated research solutions provider focused on developing cutting-edge platforms for cancer therapy and preclinical studies. The team of seasoned scientists, bioinformatics experts, and clinical oncology professionals work collaboratively to design, engineer, and validate innovative cell therapies tailored to the unique challenges of tumors. Currently, Creative Biogene is proud to announce its innovative approach to CAR-T development through the in vivo RNA-based CAR-T...]]></description>
                </item>
                <item>
                <title>Aspire Biopharma Issues Shareholder Letter</title>
                <link>https://www.pharmiweb.com/press-release/2026-05-28/aspire-biopharma-issues-shareholder-letter</link>
                <pubDate>Thu, 28 May 2026 08:30:00 +00:00</pubDate>
                <guid isPermaLink="false">234141</guid>
                <description><![CDATA[ESTERO, FL / ACCESS Newswire / May 28, 2026 / Aspire Biopharma Holdings, Inc. (Nasdaq:ASBP) (&quot;Aspire&quot; or the &quot;Company&quot;), a biopharmaceutical company developing multi-faceted patent-pending drug delivery technology, today issued the following letter to shareholders from Chief Executive Officer Kraig Higginson.Dear Fellow Shareholders,2026 is shaping up to be a defining year for Aspire Biopharma Holdings. We are moving with speed to transform our clinical pipeline into commercial reality, broad...]]></description>
                </item>
                <item>
                <title>Wellgistics Health Announces Lock-Up Agreement with Holders of a Majority of its Common Stock</title>
                <link>https://www.pharmiweb.com/press-release/2026-05-28/wellgistics-health-announces-lock-up-agreement-with-holders-of-a-majority-of-its-common-stock</link>
                <pubDate>Thu, 28 May 2026 07:40:00 +00:00</pubDate>
                <guid isPermaLink="false">234140</guid>
                <description><![CDATA[Holders of 1,333,930 common shares agree to minimum 90-day lock-up agreement TAMPA, FL / ACCESS Newswire / May 28, 2026 / Wellgistics Health, Inc. (&quot;Wellgistics&quot;) (NASDAQ:WGRX), a Health IT leader, integrating pharmacy dispensing AI platform EinsteinRx™ into patented pharmacy smart contracts platform PharmacyChain™, today announced that holders of a 1,333,930 common shares, representing a majority of the outstanding common shares of the Company, have entered into a lock-up agreement that prec...]]></description>
                </item>
                <item>
                <title>Phase 1 Equity Announces Its Third Practice Addition of the Year, Bringing on a Multi-Site Orthodontic Practice Located in Texas</title>
                <link>https://www.pharmiweb.com/press-release/2026-05-28/phase-1-equity-announces-its-third-practice-addition-of-the-year-bringing-on-a-multi-site-orthodont</link>
                <pubDate>Thu, 28 May 2026 08:00:00 +00:00</pubDate>
                <guid isPermaLink="false">234139</guid>
                <description><![CDATA[CHICAGO, IL / ACCESS Newswire / May 28, 2026 / Phase 1 Equity, a doctor-owned, doctor-led, and doctor-governed platform for orthodontists and pediatric dentists, is excited to welcome another leading multi-site orthodontic practice based in Texas to its growing network.This practice ensures each patient feels welcomed and is treated in a comfortable, kind, and family-friendly environment. They offer highly personalized care, backed by advanced orthodontic techniques and driven expertise. This...]]></description>
                </item>
                <item>
                <title>Aptevo Therapeutics Appoints Mary J. Janatpour, Ph.D., as Senior Vice President &amp; Chief Scientific Officer</title>
                <link>https://www.pharmiweb.com/press-release/2026-05-28/aptevo-therapeutics-appoints-mary-j-janatpour-phd-as-senior-vice-president-chief-scientific-o</link>
                <pubDate>Thu, 28 May 2026 08:05:00 +00:00</pubDate>
                <guid isPermaLink="false">234138</guid>
                <description><![CDATA[Experienced oncology R&amp;amp;D leader appointed to support Aptevo&#39;s expanding oncology pipeline and new radiopharmaceutical development strategy SEATTLE, WA / ACCESS Newswire / May 28, 2026 / Aptevo Therapeutics Inc. (Nasdaq:APVO), a clinical-stage biotechnology company developing novel immuno-oncology therapeutics based on its proprietary ADAPTIR™ and ADAPTIR-FLEX™ platform technologies, today announced the appointment of Mary J. Janatpour, Ph.D., as Senior Vice President &amp;amp; Chief Scientifi...]]></description>
                </item>
                <item>
                <title>Black Book to Release 2026 Top Vendor Client Satisfaction Results Ahead of AHIP26 and HFMA Annual Conferences</title>
                <link>https://www.pharmiweb.com/press-release/2026-05-28/black-book-to-release-2026-top-vendor-client-satisfaction-results-ahead-of-ahip26-and-hfma-annual-co</link>
                <pubDate>Thu, 28 May 2026 08:10:00 +00:00</pubDate>
                <guid isPermaLink="false">234137</guid>
                <description><![CDATA[Thousands of validated payer IT users and provider finance, business office, RCM and reimbursement professionals contribute category-specific evaluations across 90 healthcare technology and managed services functions WASHINGTON, D.C. / ACCESS Newswire / May 28, 2026 / Black Book Research today announced that it will release two major waves of 2026 client satisfaction results next week, ahead of two of healthcare&#39;s most important executive conferences: AHIP26, scheduled for June 9-10, 2026, at...]]></description>
                </item>
                <item>
                <title>TRNR Updates Investor Presentation Detailing Acquisition Strategy and Increased M&amp;A Pipeline</title>
                <link>https://www.pharmiweb.com/press-release/2026-05-28/trnr-updates-investor-presentation-detailing-acquisition-strategy-and-increased-ma-pipeline</link>
                <pubDate>Thu, 28 May 2026 08:30:00 +00:00</pubDate>
                <guid isPermaLink="false">234136</guid>
                <description><![CDATA[AUSTIN, TX / ACCESS Newswire / May 28, 2026 / Interactive Strength Inc. (Nasdaq:TRNR) (&quot;TRNR&quot; or the &quot;Company&quot;), maker of innovative specialty fitness equipment under the Wattbike, CLMBR, FORME and Ergatta brands, today published an updated investor presentation detailing its acquisition-driven operating strategy, the contribution of recently completed acquisitions, and an increased M&amp;amp;A pipeline.The updated presentation reflects the Company&#39;s transformation through the Wattbike and Ergatt...]]></description>
                </item>
                <item>
                <title>Faron Pharmaceuticals Ltd: Special Rights attached to the First and Second Tranche of Bonds</title>
                <link>https://www.pharmiweb.com/press-release/2026-05-28/faron-pharmaceuticals-ltd-special-rights-attached-to-the-first-and-second-tranche-of-bonds</link>
                <pubDate>Thu, 28 May 2026 08:42:00 +00:00</pubDate>
                <guid isPermaLink="false">234135</guid>
                <description><![CDATA[TURKU, FI / ACCESS Newswire / May 28, 2026 / Faron Pharmaceuticals (HEL:FARON)(LSE:FARN), a clinical-stage biopharmaceutical company focused on tackling cancers via novel immunotherapies, announces that the Board has resolved, based on the authorisation granted by the General Meeting held on 4 May 2026, to issue 8,000,000 additional Special Rights in connection with the First and Second Tranche of Bonds (originally announced on 3 April 2025 and 11 December 2025). 4,000,000 of the Special Righ...]]></description>
                </item>
                <item>
                <title>Protagonist Therapeutics to Participate in Two Investment Bank Conferences in June 2026</title>
                <link>https://www.pharmiweb.com/press-release/2026-05-28/protagonist-therapeutics-to-participate-in-two-investment-bank-conferences-in-june-2026</link>
                <pubDate>Thu, 28 May 2026 07:05:00 +00:00</pubDate>
                <guid isPermaLink="false">234134</guid>
                <description><![CDATA[NEWARK, CA / ACCESS Newswire / May 28, 2026 / Protagonist Therapeutics (Nasdaq:PTGX) (&quot;Protagonist&quot; or &quot;the Company&quot;) today announced that Dinesh V. Patel, Ph.D., President and Chief Executive Officer, will participate in two investment bank conferences taking place in June 2026.2026 Jefferies Global Healthcare Conference; New York, NY - June 2-4, 2026Format: Fireside ChatDay/Time: Wednesday, June 3 at 9:55 A.M. ETWebcast: https://event.summitcast.com/view/NgCqua4VVQjq9ibVWHVWca/STGS2oumT8ZPx...]]></description>
                </item>
                <item>
                <title>Cathpax rolls out new radiation protection system Nova-X&#174;across EMEA following very promising clinical results</title>
                <link>https://www.pharmiweb.com/press-release/2026-05-28/cathpax-rolls-out-new-radiation-protection-system-nova-x-across-emea-following-very-promising-clinic</link>
                <pubDate>Thu, 28 May 2026 07:00:00 +00:00</pubDate>
                <guid isPermaLink="false">234127</guid>
                <description><![CDATA[
Cathpax has signed several distribution contracts in different geographic regions and is supplying Nova-X&#174; to various neurointerventional centers



Nantes, France, May 28, 2026 – Cathpax, a spin-off of nuclear radiation protection group Lemer Pax, that designs, develops and commercializes team-wide, full-body radiation protection systems for interventional medical practitioners, today announces the commercial launch of Nova-X&#174; in Europe and the Middle East. The company has already signed se...]]></description>
                </item>
                <item>
                <title>Gene Transfer Technologies Market Research, Size, Share, Trends, Demand &amp; Growth Analysis by 2031</title>
                <link>https://www.pharmiweb.com/press-release/2026-05-27/gene-transfer-technologies-market-research-size-share-trends-demand-growth-analysis-by-2031</link>
                <pubDate>Wed, 27 May 2026 07:20:18 +00:00</pubDate>
                <guid isPermaLink="false">234078</guid>
                <description><![CDATA[Gene Transfer Technologies Market Overview:
The global Gene Transfer Technologies Market is projected to grow at a CAGR of around 10% over the next five years, driven by the rapid evolution of gene and cell therapies, increasing approvals of advanced therapeutics, rising demand for efficient transfection systems, expanding use of cell-based immunotherapies, and growing investments in genetic research and biopharmaceutical innovation.
Download Sample PDF: https://meditechinsights.com/gene-tran...]]></description>
                </item>
                <item>
                <title>Surgical Robots Market Report Summary, Segmentation, Review, Trends, Opportunities, Growth, Demand and Forecast to 2030</title>
                <link>https://www.pharmiweb.com/press-release/2026-05-27/surgical-robots-market-report-summary-segmentation-review-trends-opportunities-growth-demand-and-forecast-to-2030</link>
                <pubDate>Wed, 27 May 2026 07:32:52 +00:00</pubDate>
                <guid isPermaLink="false">234082</guid>
                <description><![CDATA[Surgical Robots Market Overview:
The global surgical robotics market is forecast to grow at a compound annual growth rate (CAGR) of 15% between 2025 and 2030. This expansion is largely driven by the rising demand for minimally invasive surgeries, continuous advancements in robotic technologies, and a growing elderly population at higher risk for chronic conditions that require surgical intervention. Surgical robots offer improved precision, quicker recovery times, and better overall patient o...]]></description>
                </item>
                <item>
                <title>US Child Care Market Research Report, Suze, Share, Growth, Analysis and Forecast to 2030</title>
                <link>https://www.pharmiweb.com/press-release/2026-05-27/us-child-care-market-research-report-suze-share-growth-analysis-and-forecast-to-2030</link>
                <pubDate>Wed, 27 May 2026 07:45:33 +00:00</pubDate>
                <guid isPermaLink="false">234084</guid>
                <description><![CDATA[US Child Care Market Overview:
The US Child Care Market is poised for steady expansion, with projections indicating an annual growth rate of around 6% over the next five years. This growth is being fueled by a combination of socioeconomic and structural changes, including increased workforce participation among parents, supportive government initiatives, growing awareness of early childhood education, rapid urbanization, and the integration of technology into child care services. Additionally...]]></description>
                </item>
                <item>
                <title>AI in Life Sciences Market Executive Summary, Segmentation, Review, Trends, Opportunities, Growth, Demand and Forecast to 2029</title>
                <link>https://www.pharmiweb.com/press-release/2026-05-28/ai-in-life-sciences-market-executive-summary-segmentation-review-trends-opportunities-growth-demand-and-forecast-to-2029</link>
                <pubDate>Thu, 28 May 2026 05:43:46 +00:00</pubDate>
                <guid isPermaLink="false">234108</guid>
                <description><![CDATA[Global AI in Life Science Market Overview
The global AI in life science market is witnessing exceptional growth and is anticipated to expand at a CAGR of nearly 25% during the forecast period. The increasing adoption of artificial intelligence technologies across healthcare, biotechnology, pharmaceutical research, and clinical applications is transforming the life sciences industry at an unprecedented pace. AI is rapidly becoming an essential technology for improving operational efficiency, a...]]></description>
                </item>
                <item>
                <title>Digital Health Market Executive Summary, Segmentation, Review, Trends, Opportunities, Growth, Demand and Forecast to 2031</title>
                <link>https://www.pharmiweb.com/press-release/2026-05-27/digital-health-market-executive-summary-segmentation-review-trends-opportunities-growth-demand-and-forecast-to-2031</link>
                <pubDate>Wed, 27 May 2026 06:57:09 +00:00</pubDate>
                <guid isPermaLink="false">234076</guid>
                <description><![CDATA[Global Digital Health Market Overview
The global digital health market is anticipated to witness remarkable growth over the next five years, registering an estimated CAGR of nearly 20–25% through 2029. Rapid digital transformation across the healthcare sector, increasing penetration of smartphones and wearable devices, rising preference for remote healthcare services, and growing investment in healthcare technologies are some of the major factors accelerating market expansion worldwide.
The h...]]></description>
                </item>
                <item>
                <title>Live Cell Imaging Market Growth - Market Analysis, Size, Share, Trends, Demand, Overview and Segment Forecast To 2029</title>
                <link>https://www.pharmiweb.com/press-release/2026-05-27/live-cell-imaging-market-growth-market-analysis-size-share-trends-demand-overview-and-segment-forecast-to-2029</link>
                <pubDate>Wed, 27 May 2026 06:54:12 +00:00</pubDate>
                <guid isPermaLink="false">234074</guid>
                <description><![CDATA[Global Live Cell Imaging Market Overview
The global live cell imaging market is poised for steady growth, with an expected compound annual growth rate (CAGR) of approximately 8–9% from 2024 to 2029. This growth is driven by the increasing demand for real-time cellular analysis across a wide range of applications, including biomedical research, drug development, and personalized medicine. As the life sciences industry continues to evolve, researchers are placing greater emphasis on understandi...]]></description>
                </item>
                <item>
                <title>Medical Devices Outsourcing Market Research Report, Types, Technology, Application and Region Forecast to 2029</title>
                <link>https://www.pharmiweb.com/press-release/2026-05-28/medical-devices-outsourcing-market-research-report-types-technology-application-and-region-forecast-to-2029</link>
                <pubDate>Thu, 28 May 2026 05:50:24 +00:00</pubDate>
                <guid isPermaLink="false">234110</guid>
                <description><![CDATA[Global Medical Devices Outsourcing Market Overview
The global medical devices outsourcing market is witnessing remarkable growth as healthcare companies increasingly rely on specialized external partners to streamline manufacturing, product development, testing, and regulatory operations. The market is expected to expand at a strong compound annual growth rate over the coming years, driven by the increasing demand for cost-efficient production models, technological innovation, and rising glob...]]></description>
                </item>
                <item>
                <title>Pharmaceutical Manufacturing Equipment Market Growth Opportunity, Developments and Regional Forecast to 2024-2029</title>
                <link>https://www.pharmiweb.com/press-release/2026-05-27/pharmaceutical-manufacturing-equipment-market-growth-opportunity-developments-and-regional-forecast-to-2024-2029</link>
                <pubDate>Wed, 27 May 2026 06:46:16 +00:00</pubDate>
                <guid isPermaLink="false">234073</guid>
                <description><![CDATA[Pharmaceutical Manufacturing Equipment Market OutlookThe pharmaceutical manufacturing equipment market is witnessing steady expansion and is projected to grow at a CAGR of 6–8% over the forecast period, driven by the increasing scale and complexity of global drug production. Rising demand for pharmaceutical products, supported by population growth, aging demographics, and the growing prevalence of chronic diseases, is significantly boosting the need for advanced manufacturing solutions. Pharm...]]></description>
                </item>
                <item>
                <title>Orthopedic Implants Market Report Predictions by Global Market Trends, Future Growth, Regional Overview and Forecast Outlook until 2030</title>
                <link>https://www.pharmiweb.com/press-release/2026-05-28/orthopedic-implants-market-report-predictions-by-global-market-trends-future-growth-regional-overview-and-forecast-outlook-until-2030</link>
                <pubDate>Thu, 28 May 2026 06:06:10 +00:00</pubDate>
                <guid isPermaLink="false">234112</guid>
                <description><![CDATA[OverviewThe global orthopedic implants market is poised for steady expansion, with an estimated CAGR of around 4% over the forecast period. This growth is strongly influenced by demographic shifts such as the rising geriatric population, which is more susceptible to musculoskeletal disorders. Lifestyle-related factors, including physical inactivity and obesity, continue to elevate the prevalence of chronic orthopedic conditions like osteoarthritis and osteoporosis.
The increasing frequency of...]]></description>
                </item>
                <item>
                <title>Biopharmaceuticals Market Research, Size, Share, Growth, Report Forecast by 2030</title>
                <link>https://www.pharmiweb.com/press-release/2026-05-28/biopharmaceuticals-market-research-size-share-growth-report-forecast-by-2030</link>
                <pubDate>Thu, 28 May 2026 07:20:41 +00:00</pubDate>
                <guid isPermaLink="false">234118</guid>
                <description><![CDATA[Biopharmaceuticals Market Overview:
The global biopharmaceuticals market is projected to grow at a compound annual growth rate (CAGR) of approximately 12% over the next five years. Key factors driving this growth include the rising prevalence of chronic diseases, rapid advancements in biotechnology, an expanding geriatric population, increased adoption of biosimilars, and growing investments in research and development.
Download Sample Copy: https://meditechinsights.com/biopharmaceuticals-mar...]]></description>
                </item>
                <item>
                <title>Kivo Expands Life Sciences Leadership Team with Appointment of Former Veeva Executive Chris Xistris </title>
                <link>https://www.pharmiweb.com/press-release/2026-05-27/kivo-expands-life-sciences-leadership-team-with-appointment-of-former-veeva-executive-chris-xistris</link>
                <pubDate>Wed, 27 May 2026 01:26:21 +00:00</pubDate>
                <guid isPermaLink="false">234098</guid>
                <description><![CDATA[PORTLAND, Ore. (May 27, 2026) - Kivo, the unified document and process management system for life sciences teams, announced today that Chris Xistris has joined the company as Vice President of Services.
Xistris brings more than 25 years of experience across Regulatory Operations, Clinical Operations, Quality systems, and enterprise software transformation. Prior to joining Kivo, he spent more than a decade at Veeva Systems, where he most recently served as Senior Director, R&amp;amp;D Services En...]]></description>
                </item>
                <item>
                <title>African Pharmaceutical Market Report, Size, Share, Trends, Demand by Growth and Forecast to 2029</title>
                <link>https://www.pharmiweb.com/press-release/2026-05-28/african-pharmaceutical-market-report-size-share-trends-demand-by-growth-and-forecast-to-2029</link>
                <pubDate>Thu, 28 May 2026 07:04:21 +00:00</pubDate>
                <guid isPermaLink="false">234114</guid>
                <description><![CDATA[African Pharmaceutical Market Overview
The African pharmaceutical market is projected to grow at a compound annual rate of approximately 6–8% through 2029. This growth is driven by population expansion, rapid urbanization, rising prevalence of chronic and infectious diseases, and increasing healthcare expenditure across the continent. However, market growth continues to face constraints such as limited healthcare infrastructure and the high cost of pharmaceutical manufacturing.
Download Sampl...]]></description>
                </item>
                <item>
                <title>Electrophysiology Market Research, Size, Competitor Ranking Analysis, Market Trend Forecast Report 2025-2030</title>
                <link>https://www.pharmiweb.com/press-release/2026-05-28/electrophysiology-market-research-size-competitor-ranking-analysis-market-trend-forecast-report-2025-2030</link>
                <pubDate>Thu, 28 May 2026 07:34:44 +00:00</pubDate>
                <guid isPermaLink="false">234120</guid>
                <description><![CDATA[Electrophysiology Market Overview:
The global electrophysiology market, valued at $6.7 billion in 2021, is projected to grow at a rate of 12% over the next five years. This expansion is driven by rising cardiac ablation procedure volumes, a rapidly growing geriatric population susceptible to related conditions, an increasing number of electrophysiology labs, the introduction of technologically advanced products, and significant investments and funding from both industry players and government...]]></description>
                </item>
                <item>
                <title>New phase III Translational Data Show DiviTum(R) TKa Captures Treatment-Specific Biological Response in Metastatic Breast Cancer</title>
                <link>https://www.pharmiweb.com/press-release/2026-05-28/new-phase-iii-translational-data-show-divitum-r-tka-captures-treatment-specific-biological-response</link>
                <pubDate>Thu, 28 May 2026 02:50:00 +00:00</pubDate>
                <guid isPermaLink="false">234116</guid>
                <description><![CDATA[UPPSALA, SE / ACCESS Newswire / May 28, 2026 / Biovica International (STO:BIOVIC-B)(STO:BIOVIC.B)(FRA:9II) - Biovica, specializing in blood-based cancer monitoring, today announced new data published in the European Journal of Cancer showing that DiviTumTKa can capture early, treatment-specific biological response in patients with endocrine-resistant HR+/HER2− metastatic breast cancer.The analysis included 555 patients from the phase III GEICAM/2013-02 PEARL trial and used Biovica&#39;s FDA 510(k...]]></description>
                </item>
                <item>
                <title>Applications are Open for the 2026 Semmelweis-Richter Journalism Award Until June 9th</title>
                <link>https://www.pharmiweb.com/press-release/2026-05-28/applications-are-open-for-the-2026-semmelweis-richter-journalism-award-until-june-9th</link>
                <pubDate>Thu, 28 May 2026 03:00:00 +00:00</pubDate>
                <guid isPermaLink="false">234115</guid>
                <description><![CDATA[BUDAPEST, HUNGARY / ACCESS Newswire / May 28, 2026 / After the strong success of its first edition, the Semmelweis-Richter Journalism Award returns in 2026. Journalists from eligible European countries are invited to submit entries in two categories: Women&#39;s Health and Pharmaceutical Strategies and Innovation, with a special focus on cardiovascular therapies. The application deadline is June 9, 2026, 23:59 CET.The international award was first launched in 2025 by Semmelweis University, Hungar...]]></description>
                </item>
                <item>
                <title>Wellgistics Health Refinances Outstanding Convertible Debt and Raises $6.5M</title>
                <link>https://www.pharmiweb.com/press-release/2026-05-27/wellgistics-health-refinances-outstanding-convertible-debt-and-raises-65m</link>
                <pubDate>Wed, 27 May 2026 05:50:00 +00:00</pubDate>
                <guid isPermaLink="false">234105</guid>
                <description><![CDATA[New oversubscribed $21 million convertible debt instrument (&quot;New Debt&quot;) refinances all outstanding convertible debt, provides $6.5 million in new capital for working capital and general corporate purposes does not accrue interest and converts into common shares at $6.00 per shareAutomatic Exchange provision automatically converts the New Debt into Preferred Stock upon the effectiveness of a registration statement and attainment of shareholder approval for the creation of Preferred StockThe cl...]]></description>
                </item>
                <item>
                <title>ClearPoint Neuro Enters into 10-year Focused Ultrasound Development Partnership with Sungkyunkwan University, South Korea, Further Expanding Our Drug Delivery Ecosystem and Global Footprint</title>
                <link>https://www.pharmiweb.com/press-release/2026-05-27/clearpoint-neuro-enters-into-10-year-focused-ultrasound-development-partnership-with-sungkyunkwan-un</link>
                <pubDate>Wed, 27 May 2026 04:30:00 +00:00</pubDate>
                <guid isPermaLink="false">234104</guid>
                <description><![CDATA[Announcement is made after successful proof-of-concept trial in a preclinical model of intravenous delivery of large molecule tracers across the blood-brain barrier guided by prototype systems, including both focused ultrasound hardware and ClearPoint Navigation Software and Robotics SOLANA BEACH, CA / ACCESS Newswire / May 27, 2026 / ClearPoint Neuro, Inc. (NASDAQ:CLPT) (&quot;Company&quot;), a global device, cell, and gene therapy-enabling company offering precise navigation to the brain and spine, t...]]></description>
                </item>
                <item>
                <title>NordicNeuroLab and GE HealthCare Enter Strategic Software License and Distribution Agreement to Advance Neuroimaging Worldwide</title>
                <link>https://www.pharmiweb.com/press-release/2026-05-27/nordicneurolab-and-ge-healthcare-enter-strategic-software-license-and-distribution-agreement-to-adva</link>
                <pubDate>Wed, 27 May 2026 11:20:00 +00:00</pubDate>
                <guid isPermaLink="false">234103</guid>
                <description><![CDATA[A collaboration for advancing neuroimaging MILWAUKEE, WI / ACCESS Newswire / May 27, 2026 / NordicNeuroLab announced the signing of a comprehensive Software License and Distribution Agreement with GE HealthCare.    The agreement establishes a long-term global framework for the integration, distribution, and support of NordicNeuroLab&#39;s advanced neuroimaging software within GE HealthCare&#39;s MRI ecosystem.    Under the agreement, GE HealthCare will integrate and distribute NordicNeuroLab&#39;s functi...]]></description>
                </item>
                <item>
                <title>OSR Holdings Acquires Full VXM01 Intellectual Property Portfolio in $30 Million Transaction</title>
                <link>https://www.pharmiweb.com/press-release/2026-05-27/osr-holdings-acquires-full-vxm01-intellectual-property-portfolio-in-30-million-transaction</link>
                <pubDate>Wed, 27 May 2026 09:06:00 +00:00</pubDate>
                <guid isPermaLink="false">234100</guid>
                <description><![CDATA[Transaction Centralizes VXM01 Ownership and Long-Term Royalty Economics at the OSRH Parent Level BELLEVUE, WA / ACCESS Newswire / May 27, 2026 / OSR Holdings, Inc. (NASDAQ:OSRH), a global healthcare holding company focused on innovative therapeutics and healthcare technologies, today announced it has entered into a definitive Asset Purchase Agreement (&quot;APA&quot;) with VAXIMM AG (&quot;Vaximm&quot;) to acquire the full global intellectual property portfolio and related assets for an aggregate purchase price...]]></description>
                </item>
                <item>
                <title>Jaguar Health Compliant with Nasdaq Bid Price Rule</title>
                <link>https://www.pharmiweb.com/press-release/2026-05-27/jaguar-health-compliant-with-nasdaq-bid-price-rule</link>
                <pubDate>Wed, 27 May 2026 09:00:00 +00:00</pubDate>
                <guid isPermaLink="false">234099</guid>
                <description><![CDATA[JAGX&#39;s securities continue to be listed and traded on Nasdaq SAN FRANCISCO, CA / ACCESS Newswire / May 27, 2026 / Jaguar Health, Inc. (NASDAQ:JAGX) (&quot;Jaguar&quot; or the &quot;Company&quot;) today announced that on May 26, 2026, the Company received formal notice from The Nasdaq Stock Market LLC (&quot;Nasdaq&quot;) that Jaguar has regained compliance with Nasdaq Listing Rule 5550(a)(2) (the &quot;Bid Price Rule&quot;).&quot;We are very happy that Jaguar has regained compliance with the Nasdaq listing criteria. We consider our Nasd...]]></description>
                </item>
                <item>
                <title>Aptevo and Niowave Launch Strategic Collaboration for Radiopharmaceutical Therapeutic Development, Includes Strategic Equity Investment by Niowave at Closing</title>
                <link>https://www.pharmiweb.com/press-release/2026-05-27/aptevo-and-niowave-launch-strategic-collaboration-for-radiopharmaceutical-therapeutic-development-i</link>
                <pubDate>Wed, 27 May 2026 08:05:00 +00:00</pubDate>
                <guid isPermaLink="false">234095</guid>
                <description><![CDATA[50/50 Strategic Collaboration Will Develop Up to Three Radiopharmaceutical ProgramsInnovation and Investment Continue to Accelerate Across Radiopharmaceutical Oncology SEATTLE, WA AND LANSING, MI / ACCESS Newswire / May 27, 2026 / Aptevo Therapeutics Inc. (Nasdaq:APVO), a clinical-stage biotechnology company developing novel multispecific immuno-oncology therapeutics based on its proprietary ADAPTIR™ and ADAPTIR-FLEX™ platform technologies, and Niowave, Inc., a leader in radioisotope producti...]]></description>
                </item>
                <item>
                <title>MIRA Pharmaceuticals Secures Worldwide Rights for Ketamir-2, Expanding Global IP Portfolio Across 10 Major Markets Ahead of Phase 2a in CIPN </title>
                <link>https://www.pharmiweb.com/press-release/2026-05-27/mira-pharmaceuticals-secures-worldwide-rights-for-ketamir-2-expanding-global-ip-portfolio-across-10</link>
                <pubDate>Wed, 27 May 2026 08:00:00 +00:00</pubDate>
                <guid isPermaLink="false">234094</guid>
                <description><![CDATA[Expanded Global Intellectual Property Portfolio Enhances Strategic Flexibility and Long-Term Value Potential for Ketamir-2 MIAMI, FL / ACCESS Newswire / May 27, 2026 / MIRA Pharmaceuticals, Inc. (NASDAQ:MIRA) (&quot;MIRA&quot; or the &quot;Company&quot;), a clinical-stage pharmaceutical company focused on the development of proprietary therapeutics for neurologic, neuropsychiatric, inflammatory, and metabolic disorders, today announced the execution of Amendment No. 1 to its exclusive Ketamir-2 license agreement...]]></description>
                </item>
                <item>
                <title>Aspire Biopharma&#39;s BUZZ BOMBTM Partners with EoS Fitness to Empower High-Performance Lifestyles for Millions of Members</title>
                <link>https://www.pharmiweb.com/press-release/2026-05-27/aspire-biopharmas-buzz-bombtm-partners-with-eos-fitness-to-empower-high-performance-lifestyles-for</link>
                <pubDate>Wed, 27 May 2026 08:30:00 +00:00</pubDate>
                <guid isPermaLink="false">234093</guid>
                <description><![CDATA[ESTERO, FL / ACCESS Newswire / May 27, 2026 / Aspire Biopharma Holdings, Inc.&#39;s (Nasdaq:ASBP) (&quot;Aspire&quot; or the &quot;Company&quot;) wholly owned subsidiary Buzz Bomb Caffeine Company LC is proud to announce a strategic partnership with EoS Fitness, the High Value. Low Price.&#174; (HVLP) gym chain with more than 225 locations open or on the way nationwide. Through the EoS Flex Deals affiliate program, BUZZ BOMB™ &#39;s lineup of 50mg sublingual caffeine stick packs will now be available to an expansive communit...]]></description>
                </item>
                <item>
                <title>Amphastar Pharmaceuticals to Present at the 2026 Jefferies Healthcare Conference </title>
                <link>https://www.pharmiweb.com/press-release/2026-05-27/amphastar-pharmaceuticals-to-present-at-the-2026-jefferies-healthcare-conference</link>
                <pubDate>Wed, 27 May 2026 06:00:00 +00:00</pubDate>
                <guid isPermaLink="false">234089</guid>
                <description><![CDATA[RANCHO CUCAMONGA, CA / ACCESS Newswire / May 27, 2026 / Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) announced today that Bill Peters, CFO, and Jacob Liawatidewi, EVP of Corporate Administration, will be presenting at the 2026 Jefferies Healthcare Conference on Wednesday, June 3, 2026, at 4:55 p.m. ET. For access to the webcast, visit Amphastar Pharmaceuticals&#39; website at http://ir.amphastar.com. This webcast will be available for 30 days following the presentation.About Amphastar Pharmaceut...]]></description>
                </item>
                <item>
                <title>Botox Certification for Nurses </title>
                <link>https://www.pharmiweb.com/press-release/2026-05-27/botox-certification-for-nurses</link>
                <pubDate>Wed, 27 May 2026 06:00:00 +00:00</pubDate>
                <guid isPermaLink="false">234088</guid>
                <description><![CDATA[The Best Botox certification for nurses is through AACM SEATTLE, WA / ACCESS Newswire / May 27, 2026 / As the cosmetic injectables market continues to expand across the United States, registered nurses and nurse practitioners are increasingly turning to accredited certification programs to enter the field of aesthetic medicine. Among available options, the American Academy of Cosmetic Medicine&#174; (AACM™) is recognized as one of the leading choices for nurses seeking online Botox certification a...]]></description>
                </item>
                <item>
                <title>D&amp;D Pharmatech Announces Positive 48-Week Histology Results for Zabopegdutide (DD01), Demonstrating Statistically Significant Fibrosis Improvement and MASH Resolution</title>
                <link>https://www.pharmiweb.com/press-release/2026-05-27/dd-pharmatech-announces-positive-48-week-histology-results-for-zabopegdutide-dd01-demonstrating</link>
                <pubDate>Wed, 27 May 2026 10:38:00 +00:00</pubDate>
                <guid isPermaLink="false">234085</guid>
                <description><![CDATA[

All key histological endpoints achieved with statistical significance

50.0% of patients achieved ≥1-stage fibrosis improvement with no worsening of MASH, compared to 15.8% for placebo

62.5% achieved MASH resolution with no worsening of fibrosis, versus 5.3% for placebo

37.5% achieved both fibrosis improvement and MASH resolution, compared to 5.3% for placebo

Results support potential best-in-class profile for once-weekly GLP-1/glucagon dual agonist in MASH
GYEONGGI-DO, South Korea &amp;amp;...]]></description>
                </item>
                <item>
                <title>BLEEDnFIRE Therapeutics launches with non-dilutive funding to advance first-in-class pan-indication therapy for rare bleeding disorders</title>
                <link>https://www.pharmiweb.com/press-release/2026-05-27/bleednfire-therapeutics-launches-with-non-dilutive-funding-to-advance-first-in-class-pan-indication</link>
                <pubDate>Wed, 27 May 2026 09:15:00 +00:00</pubDate>
                <guid isPermaLink="false">234087</guid>
                <description><![CDATA[
BLEEDnFIRE pioneers first RNA therapy targeting protein S, key regulator of coagulation cascade, offering new therapeutic strategy for patients across multiple rare bleeding disorders



Support from Innosuisse and Venture Kick positions BLEEDnFIRE for next stage development and financing round



Bern, Switzerland, May 27, 2026 – BLEEDnFIRE Therapeutics (BnF), an early-stage Swiss biotechnology company specializing in differentiated first-in-class RNA therapies for rare bleeding disorders,...]]></description>
                </item>
                <item>
                <title>From Science to Practice: Senzime Obtains FDA 510(k) Clearance for Enhanced TetraGraph System</title>
                <link>https://www.pharmiweb.com/press-release/2026-05-27/from-science-to-practice-senzime-obtains-fda-510-k-clearance-for-enhanced-tetragraph-system</link>
                <pubDate>Wed, 27 May 2026 05:35:00 +00:00</pubDate>
                <guid isPermaLink="false">234086</guid>
                <description><![CDATA[UPPSALA, SE / ACCESS Newswire / May 27, 2026 / Senzime (STO:SEZI)(OTCQX:SNZZF) - Senzime AB today announced that its TetraGraph&#174; neuromuscular monitoring system has received an additional FDA Class II 510(k) clearance. The new FDA clearance follows submission in April 2026 and expands the system&#39;s capabilities, further strengthening the TetraGraph&#39;s competitive advantages.The new 510(k) clearance includes, among other things, unique capabilities of the next-generation TetraGraph system, and a...]]></description>
                </item>
                <item>
                <title>ABIONYX Pharma Launches Fully Secured Capital Increase with Preferential Subscription Rights and Structured Debt Financing for an Aggregate Amount of up to c. EUR 33 M</title>
                <link>https://www.pharmiweb.com/press-release/2026-05-27/abionyx-pharma-launches-fully-secured-capital-increase-with-preferential-subscription-rights-and-str</link>
                <pubDate>Wed, 27 May 2026 08:30:00 +00:00</pubDate>
                <guid isPermaLink="false">234066</guid>
                <description><![CDATA[

Size of the Fully Guaranteed Capital Increase with subscription rights: EUR 32.7m

Subscription ratio: 1 new share for every 5 existing shares

Subscription price: 2.65 euro per new share

Subscription Rights Trading Period: from May 29 to June 11, 2026 included

Theorical value of subscription right: 0.1375 euro

Subscription Period: from June 2 to June 15, 2026 included

Firm commitment from Fenja Capital, a Scandinavian fund acting as the Company’s new lead investor - investing outside i...]]></description>
                </item>
                <item>
                <title>Median Technologies Launches a Capital Increase of €40 million, with Potential Upsize to €50 million, to Support the Deployment of eyonis&#174; LCS in the U.S. and Europe and Advance New Clinical Indications for Its Proprietary eyonis&#174;...</title>
                <link>https://www.pharmiweb.com/press-release/2026-05-27/median-technologies-launches-a-capital-increase-of-40-million-with-potential-upsize-to-50-million</link>
                <pubDate>Wed, 27 May 2026 08:00:00 +00:00</pubDate>
                <guid isPermaLink="false">234068</guid>
                <description><![CDATA[

Share capital increase without shareholders’ preferential subscription rights, to be carried out by way of an issue of ordinary shares in the framework of a public offering, for an amount of approximately 40 million euros.

A share capital increase without shareholders’ preferential subscription rights reserved for the Guarantors (as defined below) for a maximum amount of 10 million euros, should all the ordinary shares issued in the framework of the public offering be fully subscribed;

Fi...]]></description>
                </item>
                <item>
                <title>Acurex Biosciences Awarded ASAP Grant to Advance Breakthrough Approach to Parkinson’s Disease</title>
                <link>https://www.pharmiweb.com/press-release/2026-05-27/acurex-biosciences-awarded-asap-grant-to-advance-breakthrough-approach-to-parkinson-s-disease</link>
                <pubDate>Wed, 27 May 2026 07:39:00 +00:00</pubDate>
                <guid isPermaLink="false">234067</guid>
                <description><![CDATA[
Award funds collaboration with leading Parkinson’s researcher, Dr. Tim Greenamyre, to investigate a novel therapeutic approach for Parkinson’s disease      SAN CARLOS, Calif.--(BUSINESS WIRE)--Acurex Biosciences, a biotechnology company developing new medicines for Parkinson’s disease and other neurological disorders, today announced it has been awarded a grant from Aligning Science Across Parkinson’s (ASAP) in partnership with The Michael J. Fox Foundation for Parkinson’s Research (MJFF).
T...]]></description>
                </item>
                <item>
                <title>FluoGuide A/S Publishes Interim Report for Q1 2026</title>
                <link>https://www.pharmiweb.com/press-release/2026-05-27/fluoguide-as-publishes-interim-report-for-q1-2026</link>
                <pubDate>Wed, 27 May 2026 01:30:00 +00:00</pubDate>
                <guid isPermaLink="false">234069</guid>
                <description><![CDATA[K&#216;BENHAVN, DK / ACCESS Newswire / May 27, 2026 / Fluoguide A/S (STO:FLUO) (&quot;FluoGuide&quot; or the &quot;Company&quot;) today releases its results for the period 1 January 2026 - 31 March 2026. The Q1 report is available as attached document to this press release and on FluoGuide&#39;s website.&quot;The first quarter marked an important step forward for FluoGuide as we advanced FG001 toward registration-directed development in the U.S. The FDA IND authorization and Fast Track Designation provide important regulatory...]]></description>
                </item>
                <item>
                <title>IQVIA CEO to Speak at Jefferies Global Healthcare Conference</title>
                <link>https://www.pharmiweb.com/press-release/2026-05-26/iqvia-ceo-to-speak-at-jefferies-global-healthcare-conference</link>
                <pubDate>Tue, 26 May 2026 11:15:00 +00:00</pubDate>
                <guid isPermaLink="false">234061</guid>
                <description><![CDATA[RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--IQVIA Holdings Inc. (“IQVIA”) (NYSE:IQV), a leading global provider of clinical research services, commercial insights and healthcare intelligence to the life sciences and healthcare industries, announced today that Ari Bousbib, chairman and chief executive officer, will speak at the Jefferies Global Healthcare Conference on Wednesday, June 3, 2026, at 9:20 a.m. ET.
A live audio webcast of the presentation will be available on the IQVIA Investor...]]></description>
                </item>
                <item>
                <title>ICON Schedules Fourth Quarter and Full Year 2025 Earnings Conference Call and Acknowledges Receipt of Deficiency Notice from Nasdaq</title>
                <link>https://www.pharmiweb.com/press-release/2026-05-26/icon-schedules-fourth-quarter-and-full-year-2025-earnings-conference-call-and-acknowledges-receipt-o</link>
                <pubDate>Tue, 26 May 2026 11:05:00 +00:00</pubDate>
                <guid isPermaLink="false">234063</guid>
                <description><![CDATA[DUBLIN--(BUSINESS WIRE)--ICON plc (NASDAQ: ICLR), a world-leading clinical research organization, today announced that it will release financial results for the fourth quarter and full year 2025 results after the market closes on Wednesday, May 27, 2026. The Company will hold a conference call and webcast to discuss its financial results and performance on Thursday, May 28, 2026 at 8:00am ET.
The Company also announced that, as expected, as a consequence of not yet having filed its Annual Rep...]]></description>
                </item>
                <item>
                <title>Marea Therapeutics to Present Data from Phase 1 Study of MAR002 for the Treatment of Acromegaly at ENDO 2026</title>
                <link>https://www.pharmiweb.com/press-release/2026-05-26/marea-therapeutics-to-present-data-from-phase-1-study-of-mar002-for-the-treatment-of-acromegaly-at-e</link>
                <pubDate>Tue, 26 May 2026 11:00:00 +00:00</pubDate>
                <guid isPermaLink="false">234062</guid>
                <description><![CDATA[SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Marea Therapeutics, Inc., a clinical-stage biotechnology company harnessing the latest advances in human genetics to develop first-in-class, next-generation medicines for cardioendocrine diseases, today announced that data from its first-in-human Phase 1 study of MAR002 will be highlighted in an oral presentation at the 2026 Annual Meeting of the Endocrine Society (ENDO), being held from June 13-16 in Chicago, IL.
MAR002 is a first-in-class allost...]]></description>
                </item>
                <item>
                <title>DELAYED AGAIN! Will Marijuana Rescheduling Survive Constitutional Challenges, Treaty Conflicts, and Federal Court Scrutiny?</title>
                <link>https://www.pharmiweb.com/press-release/2026-05-26/delayed-again-will-marijuana-rescheduling-survive-constitutional-challenges-treaty-conflicts-and</link>
                <pubDate>Tue, 26 May 2026 05:50:00 +00:00</pubDate>
                <guid isPermaLink="false">234064</guid>
                <description><![CDATA[Federally Compliant Pharmaceutical Developer Raises Constitutional, Statutory, Treaty, and Competitive Fairness Objections - Reserves Right to Seek Federal Court Review WASHINGTON, D.C. / ACCESS Newswire / May 26, 2026 / MMJ International Holdings, together with its subsidiaries MMJ BioPharma Cultivation, and MMJ BioPharma Labs, (collectively, &quot;MMJ&quot;), formally announced today that it will file a Notice of Intent to Participate in the Drug Enforcement Administration&#39;s (DEA) administrative hear...]]></description>
                </item>
                <item>
                <title>Local Healthcare Executive Randee Lacon Appointed Chief Operating Officer of Cedar Oaks Wellness Center</title>
                <link>https://www.pharmiweb.com/press-release/2026-05-26/local-healthcare-executive-randee-lacon-appointed-chief-operating-officer-of-cedar-oaks-wellness-cen</link>
                <pubDate>Tue, 26 May 2026 05:25:00 +00:00</pubDate>
                <guid isPermaLink="false">234060</guid>
                <description><![CDATA[CINCINNATI, OH / ACCESS Newswire / May 26, 2026 / Cedar Oaks Wellness Center, a CARF-accredited provider of comprehensive drug, alcohol, and mental health treatment services in Southwest Ohio, today announced the appointment of Randee Lacon, LISW-S, LICDC as its new Chief Operating Officer.The appointment comes as Cedar Oaks Wellness Center continues to grow its clinical programs and deepen its commitment to accessible, evidence-based behavioral health care in the Greater Cincinnati region -...]]></description>
                </item>
                <item>
                <title>Merck Announces Third-Quarter 2026 Dividend</title>
                <link>https://www.pharmiweb.com/press-release/2026-05-26/merck-announces-third-quarter-2026-dividend</link>
                <pubDate>Tue, 26 May 2026 08:28:00 +00:00</pubDate>
                <guid isPermaLink="false">234049</guid>
                <description><![CDATA[RAHWAY, N.J.--(BUSINESS WIRE)--Merck (NYSE: MRK), known as MSD outside of the United States and Canada, announced today that the Board of Directors has declared a quarterly dividend of $0.85 per share of the company’s common stock for the third quarter of 2026. Payment will be made on July 8, 2026, to shareholders of record at the close of business on June 15, 2026.
About Merck
At Merck, known as MSD outside of the United States and Canada, we are unified around our purpose: We use the power...]]></description>
                </item>
                <item>
                <title>Riassunto: Merz Therapeutics e Kvvit stipulano un accordo esclusivo per INBRIJA&#174; (levodopa polvere per inalazione) nella Cina continentale, a Hong Kong e Macao</title>
                <link>https://www.pharmiweb.com/press-release/2026-05-26/riassunto-merz-therapeutics-e-kvvit-stipulano-un-accordo-esclusivo-per-inbrija-levodopa-polvere-p</link>
                <pubDate>Tue, 26 May 2026 08:05:00 +00:00</pubDate>
                <guid isPermaLink="false">234050</guid>
                <description><![CDATA[

Kvvit guider&#224; lo sviluppo locale, le attivit&#224; normative e la commercializzazione di INBRIJA&#174; nella Cina continentale, a Hong Kong e a Macao​

Secondo i termini dell&#39;accordo, Merz Therapeutics ricever&#224; pagamenti milestone di tre tipi: anticipati, allo scadere di determinate fasi di sviluppo e al raggiungimento di traguardi commerciali, nonch&#233; accordi di fornitura e royalty a pi&#249; livelli, senza rilascio di diritti di produzione a Kvvit​
FRANCOFORTE, Germania e GANZHOU, Cina--(BUSINESS WIRE)--...]]></description>
                </item>
                <item>
                <title>Resumen: Merz Therapeutics y Kvvit firman un acuerdo exclusivo para INBRIJA&#174; (levodopa en polvo para inhalaci&#243;n) en China continental, Hong Kong y Macao</title>
                <link>https://www.pharmiweb.com/press-release/2026-05-26/resumen-merz-therapeutics-y-kvvit-firman-un-acuerdo-exclusivo-para-inbrija-levodopa-en-polvo-para</link>
                <pubDate>Tue, 26 May 2026 08:05:00 +00:00</pubDate>
                <guid isPermaLink="false">234051</guid>
                <description><![CDATA[

Kvvit se encargar&#225; del desarrollo local, los tr&#225;mites regulatorios y la comercializaci&#243;n de INBRIJA&#174; en China continental, Hong Kong y Macao​

En virtud del acuerdo, Merz Therapeutics recibir&#225; pagos iniciales, pagos por objetivos de desarrollo y comercializaci&#243;n, as&#237; como acuerdos de suministro y regal&#237;as escalonados, sin que se concedan derechos de fabricaci&#243;n a Kvvit.
FR&#193;NCFORT, Alemania, y GANZHOU, China--(BUSINESS WIRE)--Merz Therapeutics GmbH y Jiangxi Kvvit Pharmaceutical Co. Ltd. han...]]></description>
                </item>
                <item>
                <title>Samenvatting: Merz Therapeutics en Kvvit sluiten een exclusief akkoord voor INBRIJA&#174; (levodopa inhalatiepoeder) in het vasteland van China, Hongkong en Macao</title>
                <link>https://www.pharmiweb.com/press-release/2026-05-26/samenvatting-merz-therapeutics-en-kvvit-sluiten-een-exclusief-akkoord-voor-inbrija-levodopa-inhal</link>
                <pubDate>Tue, 26 May 2026 08:05:00 +00:00</pubDate>
                <guid isPermaLink="false">234059</guid>
                <description><![CDATA[

Kvvit zal instaan voor de lokale ontwikkeling, toezichthoudende activiteiten en de commercialisering van INBRIJA&#174; in het vasteland van China, Hongkong en Macao​

In het kader van dit akkoord zal Merz Therapeutics vooruitbetalingen, ontwikkelingsbetalingen en commerci&#235;le mijlpaalbetalingen ontvangen, alsook gelaagde leveringsvergoedingen en royalties, waarbij aan Kvvit geen productierechten worden gegund​
FRANKFURT, Duitsland &amp;amp; GANZHOU, China--(BUSINESS WIRE)--Merz Therapeutics GmbH en J...]]></description>
                </item>
                <item>
                <title>Merz Therapeutics et Kvvit concluent un accord exclusif concernant INBRIJA&#174; (poudre pour inhalation de l&#233;vodopa) en Chine continentale, &#224; Hong Kong et &#224; Macao</title>
                <link>https://www.pharmiweb.com/press-release/2026-05-26/merz-therapeutics-et-kvvit-concluent-un-accord-exclusif-concernant-inbrija-poudre-pour-inhalation</link>
                <pubDate>Tue, 26 May 2026 08:02:00 +00:00</pubDate>
                <guid isPermaLink="false">234052</guid>
                <description><![CDATA[

Kvvit dirigera le d&#233;veloppement local, les activit&#233;s r&#233;glementaires et la commercialisation d’INBRIJA&#174; en Chine continentale, &#224; Hong Kong et &#224; Macao

Aux termes de l’accord, Merz Therapeutics recevra des paiements initiaux, des paiements d’&#233;tapes li&#233;s au d&#233;veloppement et &#224; la commercialisation, ainsi que des accords d’approvisionnement et de redevances &#233;chelonn&#233;s, sans que des droits de fabrication soient accord&#233;s &#224; Kvvit
FRANCFORT, Allemagne et GANZHOU, Chine--(BUSINESS WIRE)--Merz Therape...]]></description>
                </item>
                <item>
                <title>Merz Therapeutics und Kvvit schlie&#223;en exklusive Vereinbarung f&#252;r INBRIJA&#174; (Levodopa-Inhalationspulver) in Festlandchina, Hongkong und Macao ab</title>
                <link>https://www.pharmiweb.com/press-release/2026-05-26/merz-therapeutics-und-kvvit-schliessen-exklusive-vereinbarung-fuer-inbrija-levodopa-inhalationspulve</link>
                <pubDate>Tue, 26 May 2026 08:02:00 +00:00</pubDate>
                <guid isPermaLink="false">234053</guid>
                <description><![CDATA[

Kvvit wird die lokale Entwicklung, die Zulassungsaktivit&#228;ten und die Vermarktung von INBRIJA&#174; in Festlandchina, Hongkong und Macao leiten​

Im Rahmen der Vereinbarung erh&#228;lt Merz Therapeutics Vorauszahlungen, Meilensteinzahlungen f&#252;r Entwicklung und Vermarktung sowie gestaffelte Liefer- und Lizenzvereinbarungen, wobei Kvvit keine Herstellungsrechte gew&#228;hrt werden​
FRANKFURT, Deuschland &amp;amp; GANZHOU, China--(BUSINESS WIRE)--Die Merz Therapeutics GmbH und die Jiangxi Kvvit Pharmaceutical Co....]]></description>
                </item>
                <item>
                <title>MaaT Pharma Provides Business Update and Reports Financial Results for the First Quarter 2026</title>
                <link>https://www.pharmiweb.com/press-release/2026-05-26/maat-pharma-provides-business-update-and-reports-financial-results-for-the-first-quarter-2026</link>
                <pubDate>Tue, 26 May 2026 08:00:00 +00:00</pubDate>
                <guid isPermaLink="false">234054</guid>
                <description><![CDATA[

MaaT013 (Xervyteg&#174;):


In May 2026, the Company was informed of a “negative trend” opinion on its Marketing Authorization Application from the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA), ahead of the expected CHMP formal vote in June; the Company plans to request a re-examination procedure upon the formal opinion

EBMT 2026 annual congress: MaaT Pharma presented data from the pivotal ARES trial of MaaT013 (Xervyteg&#174;) featured in the Presiden...]]></description>
                </item>
                <item>
                <title>Law Offices of Howard G. Smith Encourages Phreesia Inc. (PHR) Shareholders To Inquire About Securities Fraud Class Action</title>
                <link>https://www.pharmiweb.com/press-release/2026-05-26/law-offices-of-howard-g-smith-encourages-phreesia-inc-phr-shareholders-to-inquire-about-securiti</link>
                <pubDate>Tue, 26 May 2026 07:43:00 +00:00</pubDate>
                <guid isPermaLink="false">234055</guid>
                <description><![CDATA[BENSALEM, Pa.--(BUSINESS WIRE)--Law Offices of Howard G. Smith announces that a class action lawsuit has been filed on behalf of investors who purchased Phreesia Inc. (“Phreesia” or the “Company”) (NYSE: PHR) common stock between May 8, 2025 and March 30, 2026, inclusive (the “Class Period”). Phreesia investors have until July 13, 2026 to file a lead plaintiff motion.IF YOU ARE AN INVESTOR WHO SUFFERED A LOSS IN PHREESIA INC. (PHR), CONTACT THE LAW OFFICES OF HOWARD G. SMITH TO PARTICIPATE IN...]]></description>
                </item>
                <item>
                <title>Law Offices of Frank R. Cruz Encourages Phreesia Inc. (PHR) Shareholders To Inquire About Securities Fraud Class Action</title>
                <link>https://www.pharmiweb.com/press-release/2026-05-26/law-offices-of-frank-r-cruz-encourages-phreesia-inc-phr-shareholders-to-inquire-about-securities</link>
                <pubDate>Tue, 26 May 2026 07:06:00 +00:00</pubDate>
                <guid isPermaLink="false">234056</guid>
                <description><![CDATA[LOS ANGELES--(BUSINESS WIRE)--The Law Offices of Frank R. Cruz announces that a class action lawsuit has been filed on behalf of shareholders who purchased or otherwise acquired Phreesia Inc. (“Phreesia” or the “Company”) (NYSE: PHR) common stock between May 8, 2025 and March 30, 2026, inclusive (the “Class Period”). Phreesia investors have until July 13, 2026 to file a lead plaintiff motion.
IF YOU SUFFERED A LOSS ON YOUR PHREESIA INC. (PHR) INVESTMENTS, CLICK HERE TO SUBMIT A CLAIM TO POTEN...]]></description>
                </item>
                <item>
                <title>Medincell to Participate in Jefferies and Evercore Investor Conferences in the U.S. in June</title>
                <link>https://www.pharmiweb.com/press-release/2026-05-26/medincell-to-participate-in-jefferies-and-evercore-investor-conferences-in-the-us-in-june</link>
                <pubDate>Tue, 26 May 2026 07:00:00 +00:00</pubDate>
                <guid isPermaLink="false">234057</guid>
                <description><![CDATA[MONTPELLIER, France--(BUSINESS WIRE)--Regulatory News:
Medincell (Euronext Paris: MEDCL), a commercial- and clinical-stage biopharmaceutical licensing company developing long-acting injectable treatments, today announced that Christophe Douat, Chief Executive Officer, and Grace Kim, Chief Strategy Officer, U.S. Finance, will participate in the following leading U.S. investor conferences:
Jefferies Annual NY Biotech Conference

Dates: June 2-4, 2026

Location: New-York

Presentation: 9:55 AM E...]]></description>
                </item>
                <item>
                <title>SpineGuard Obtains Three New Patents for Full Protection in the U.S. of Its Innovative Solutions Integrating DSG Technology</title>
                <link>https://www.pharmiweb.com/press-release/2026-05-26/spineguard-obtains-three-new-patents-for-full-protection-in-the-us-of-its-innovative-solutions-int</link>
                <pubDate>Tue, 26 May 2026 07:00:00 +00:00</pubDate>
                <guid isPermaLink="false">234058</guid>
                <description><![CDATA[
All patents now granted in the United States to enhance the safety of robots, navigation systems, and powered orthopedic or dental drillsPARIS &amp;amp; BOULDER, Colo.--(BUSINESS WIRE)--Regulatory News:
SpineGuard (FR0011464452 - ALSGD), an innovative company that deploys its DSG&#174; (Dynamic Surgical Guidance) local conductivity sensing technology to secure and streamline the placement of bone implants, today announces that three new U.S. patent applications have received notices of allowance from...]]></description>
                </item>
                <item>
                <title>Neal Gerber Eisenberg Welcomes Partner Brian P. Murray to Intellectual Property Practice</title>
                <link>https://www.pharmiweb.com/press-release/2026-05-26/neal-gerber-eisenberg-welcomes-partner-brian-p-murray-to-intellectual-property-practice</link>
                <pubDate>Tue, 26 May 2026 06:51:00 +00:00</pubDate>
                <guid isPermaLink="false">234046</guid>
                <description><![CDATA[CHICAGO--(BUSINESS WIRE)--Neal Gerber Eisenberg (NGE) is pleased to announce that Brian P. Murray has joined the firm as a partner in its Intellectual Property practice group, with a focus on life sciences.
Brian brings more than a decade of experience advising clients on complex intellectual property matters across the pharmaceutical, biotechnology, and advanced technology sectors. His practice spans both patent litigation and strategic counseling, with significant experience serving as lead...]]></description>
                </item>
                <item>
                <title>Median Technologies to Showcase iCRO’s Central and AI-powered Imaging Services for Oncology Clinical Trials at ASCO 2026</title>
                <link>https://www.pharmiweb.com/press-release/2026-05-26/median-technologies-to-showcase-icro-s-central-and-ai-powered-imaging-services-for-oncology-clinical</link>
                <pubDate>Tue, 26 May 2026 06:45:00 +00:00</pubDate>
                <guid isPermaLink="false">234048</guid>
                <description><![CDATA[

Median is a leading provider of imaging services to the world’s top oncology pharma companies

Median will host two presentation sessions to introduce its new solutions for radiopharmaceutical image processing and cachexia assessment for oncology research at booth #36102
SOPHIA ANTIPOLIS, France--(BUSINESS WIRE)--Regulatory News:
Median Technologies (FR0011049824, ALMDT, “Median” or the “Company”), manufacturer of eyonis&#174;, a suite of artificial intelligence (AI) powered Software as Medical...]]></description>
                </item>
                <item>
                <title>Arrowhead Pharmaceuticals Presents New Positive Clinical Cardiometabolic Data at the 94th European Atherosclerosis Society (EAS) Congress</title>
                <link>https://www.pharmiweb.com/press-release/2026-05-26/arrowhead-pharmaceuticals-presents-new-positive-clinical-cardiometabolic-data-at-the-94th-european-a</link>
                <pubDate>Tue, 26 May 2026 05:00:00 +00:00</pubDate>
                <guid isPermaLink="false">234047</guid>
                <description><![CDATA[
- New data support potential use of plozasiran without dose adjustment in patients with moderate-to-severe renal or moderate hepatic impairment
- Case report suggests that preconception exposure to plozasiran may be associated with sustained lowering of fasting triglyceride levels throughout the term of a pregnancyPASADENA, Calif.--(BUSINESS WIRE)--$arwr--Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today presented new positive clinical data for plozasiran supporting its use in patients wi...]]></description>
                </item>
                <item>
                <title>Immutep Limited Class Action Reminder - Robbins LLP Encourages IMMP Investors to Contact the Firm for Information About Their Rights</title>
                <link>https://www.pharmiweb.com/press-release/2026-05-26/immutep-limited-class-action-reminder-robbins-llp-encourages-immp-investors-to-contact-the-firm-fo</link>
                <pubDate>Tue, 26 May 2026 04:00:00 +00:00</pubDate>
                <guid isPermaLink="false">234028</guid>
                <description><![CDATA[SAN DIEGO--(BUSINESS WIRE)--$IMMP #Biotechnology--Robbins LLP is Investigating Allegations that Immutep Limited (IMMP) Misled Investors Regarding the Viability and Efficacy of its Drug CandidateOn May 5, 2026, a class action was filed on behalf of all investors who purchased or otherwise acquired Immutep Limited American Depository Receipts (NASDAQ: IMMP) between March 24, 2025 and March 12, 2026. Immutep is an Australian-based biotechnology company focused on developing Lymphocyte Activation...]]></description>
                </item>
                <item>
                <title>Rocklin Lab Releases Megascale Open Protein Stability Dataset to Advance Biomolecular AI</title>
                <link>https://www.pharmiweb.com/press-release/2026-05-26/rocklin-lab-releases-megascale-open-protein-stability-dataset-to-advance-biomolecular-ai</link>
                <pubDate>Tue, 26 May 2026 04:00:00 +00:00</pubDate>
                <guid isPermaLink="false">234029</guid>
                <description><![CDATA[
Supported by the OpenFold Consortium, the MGnify Stability Dataset provides folding stability measurements for 1.8 million diverse protein domains, including crucial negative data needed to train better open foundation models.BERKELEY, Calif.--(BUSINESS WIRE)--The Rocklin Lab at Northwestern University today announced the release of the MGnify Stability Dataset, a large-scale experimental resource containing folding stability measurements for 1.8 million diverse protein domains. The release...]]></description>
                </item>
                <item>
                <title>LSPedia Announces Strategic Growth Investment from Bregal Sagemount</title>
                <link>https://www.pharmiweb.com/press-release/2026-05-26/lspedia-announces-strategic-growth-investment-from-bregal-sagemount</link>
                <pubDate>Tue, 26 May 2026 04:00:00 +00:00</pubDate>
                <guid isPermaLink="false">234030</guid>
                <description><![CDATA[FARMINGTON HILLS, Mich.--(BUSINESS WIRE)--LSPedia (the “Company”), a leading provider of mission-critical compliance, traceability, and supply chain software to the pharmaceutical industry, today announced a strategic growth investment from Bregal Sagemount (“Sagemount”), a leading growth-focused private equity firm, through its Basecamp fund. The investment will support LSPedia’s continued product innovation, customer expansion, and the acceleration of the Company’s global growth strategy.
F...]]></description>
                </item>
                <item>
                <title>ValGenesis to Spotlight AI’s Expanding Role in Validation at Research Triangle Park Event</title>
                <link>https://www.pharmiweb.com/press-release/2026-05-26/valgenesis-to-spotlight-ai-s-expanding-role-in-validation-at-research-triangle-park-event</link>
                <pubDate>Tue, 26 May 2026 04:00:00 +00:00</pubDate>
                <guid isPermaLink="false">234045</guid>
                <description><![CDATA[SANTA CLARA, Calif.--(BUSINESS WIRE)--ValGenesis, Inc., the market leader in digital validation, will host the next event in its global ValConnect Innovation Day series on June 2 in North Carolina’s Research Triangle Park.
Hosted in partnership with Sequence Inc., at the company’s RTP headquarters, the one-day program will bring together life sciences professionals to explore AI-powered validation, digital transformation, and the evolving role of AI in modernizing validation processes across...]]></description>
                </item>
                <item>
                <title>Vetter Achieves Platinum Status as a Best Managed Company</title>
                <link>https://www.pharmiweb.com/press-release/2026-05-26/vetter-achieves-platinum-status-as-a-best-managed-company</link>
                <pubDate>Tue, 26 May 2026 03:42:00 +00:00</pubDate>
                <guid isPermaLink="false">234031</guid>
                <description><![CDATA[
Pharmaceutical service provider receives prestigious management award for the seventh year in a row

Family-owned company once again excels in all four key business areas

Site development and digitalization as strategic investment priorities

Focus on new sources for skilled workers and on lifelong learning
RAVENSBURG, Germany--(BUSINESS WIRE)--Vetter, a leading Contract Development and Manufacturing Organization (CDMO), has been named a Best Managed Company for the seventh year in a row. T...]]></description>
                </item>
                <item>
                <title>Vetter Achieves Platinum Status as a Best Managed Company</title>
                <link>https://www.pharmiweb.com/press-release/2026-05-26/vetter-achieves-platinum-status-as-a-best-managed-company-1</link>
                <pubDate>Tue, 26 May 2026 03:42:00 +00:00</pubDate>
                <guid isPermaLink="false">234042</guid>
                <description><![CDATA[
Pharmaceutical service provider receives prestigious management award for the seventh year in a row

Family-owned company once again excels in all four key business areas

Site development and digitalization as strategic investment priorities

Focus on new sources for skilled workers and on lifelong learning
RAVENSBURG, Germany--(BUSINESS WIRE)--Vetter, a leading Contract Development and Manufacturing Organization (CDMO), has been named a Best Managed Company for the seventh year in a row. T...]]></description>
                </item>
                <item>
                <title>Biocytogen Launches AI-Powered RenSuper™ Platform and Industry-First Fully Automated Antibody Discovery Infrastructure</title>
                <link>https://www.pharmiweb.com/press-release/2026-05-26/biocytogen-launches-ai-powered-rensuper-platform-and-industry-first-fully-automated-antibody-discov</link>
                <pubDate>Tue, 26 May 2026 03:00:00 +00:00</pubDate>
                <guid isPermaLink="false">234032</guid>
                <description><![CDATA[BEIJING--(BUSINESS WIRE)--Biocytogen today announced the launch of RenSuper Workstation, a next-generation AI-powered antibody discovery platform providing off-the-shelf access to a large-scale, experimentally validated library of fully human therapeutic antibody sequences, together with the RenSuper High-Throughput Antibody Manufacturing Automation Center, a fully automated infrastructure designed to accelerate antibody validation and production.
Built on Biocytogen’s proprietary RenMice&#174; pl...]]></description>
                </item>
                <item>
                <title>Agilent Launches Multi-Attribute Method (MAM) Solution for BioPharma Quality Control</title>
                <link>https://www.pharmiweb.com/press-release/2026-05-26/agilent-launches-multi-attribute-method-mam-solution-for-biopharma-quality-control</link>
                <pubDate>Tue, 26 May 2026 03:00:00 +00:00</pubDate>
                <guid isPermaLink="false">234033</guid>
                <description><![CDATA[SANTA CLARA, Calif.--(BUSINESS WIRE)--Agilent Technologies Inc. (NYSE: A) today announced the release of a new multi-attribute method (MAM) workflow designed to help pharmaceutical and biopharmaceutical quality control (QC) laboratories implement liquid chromatography high-resolution mass spectrometry (LC/HRMS) in routine, regulated testing environments.
The Agilent MAM solution brings together software, instrumentation, columns, consumables and standards to address practical and operational...]]></description>
                </item>
                <item>
                <title>Aphios Corporation Announces Notice of Allowance for Novel Bryoid Composition Patent Targeting Alzheimer’s Disease, Multiple Sclerosis, HIV Latency and Cancer</title>
                <link>https://www.pharmiweb.com/press-release/2026-05-26/aphios-corporation-announces-notice-of-allowance-for-novel-bryoid-composition-patent-targeting-alzhe</link>
                <pubDate>Tue, 26 May 2026 03:00:00 +00:00</pubDate>
                <guid isPermaLink="false">234034</guid>
                <description><![CDATA[NORTH READING, Mass.--(BUSINESS WIRE)--#Alzheimers--Aphios Corporation today announced that the United States Patent and Trademark Office (USPTO) has issued a Notice of Allowance for a divisional patent application titled “Bryoid Compositions, Methods of Making and Use Thereof” covering novel Bryoid compounds with potential therapeutic applications in neurodegenerative diseases, HIV latency, cancer, and other amyloid-mediated disorders.
The allowed claims relate to a novel Bryoid composition...]]></description>
                </item>
                <item>
                <title>Biomunex Announces Strategic Artificial Intelligence Collaborations to Further Accelerate the Discovery and Development Processes of Its Innovative Pipeline of Cancer Immunotherapies</title>
                <link>https://www.pharmiweb.com/press-release/2026-05-26/biomunex-announces-strategic-artificial-intelligence-collaborations-to-further-accelerate-the-discov</link>
                <pubDate>Tue, 26 May 2026 03:00:00 +00:00</pubDate>
                <guid isPermaLink="false">234035</guid>
                <description><![CDATA[
Collaborations with Gordion Bioscience and Tangramed Biotech, two AI-specialized companies, further strengthen Biomunex&#39;s integration of artificial intelligence (AI) into its R&amp;amp;D activities and support the development of next generation immunotherapies in oncologyPARIS &amp;amp; CAMBRIDGE, Mass.--(BUSINESS WIRE)--Biomunex Pharmaceuticals, a biopharmaceutical company specialized in the discovery and development of innovative immunotherapies based on bispecific and multi-specific antibodies, t...]]></description>
                </item>
                <item>
                <title>Delphia Therapeutics Appoints David P. Kerstein, M.D., as Chief Medical Officer</title>
                <link>https://www.pharmiweb.com/press-release/2026-05-26/delphia-therapeutics-appoints-david-p-kerstein-md-as-chief-medical-officer</link>
                <pubDate>Tue, 26 May 2026 03:00:00 +00:00</pubDate>
                <guid isPermaLink="false">234036</guid>
                <description><![CDATA[CAMBRIDGE, Mass.--(BUSINESS WIRE)--Delphia Therapeutics, Inc. (Delphia), a biopharmaceutical company pioneering an innovative new area of cancer biology – activation lethality – which targets cancer&#39;s surprising vulnerability to oncogene overactivation, today announced the appointment of David P. Kerstein, M.D., as chief medical officer. Dr. Kerstein brings significant experience in oncology drug development across early- and late-stage precision oncology programs.
“David is an accomplished p...]]></description>
                </item>
                <item>
                <title>BNB Plus Corp. (BNBX) Secures Initial Commitments for $4.1M in Strategic Financing</title>
                <link>https://www.pharmiweb.com/press-release/2026-05-26/bnb-plus-corp-bnbx-secures-initial-commitments-for-41m-in-strategic-financing</link>
                <pubDate>Tue, 26 May 2026 03:00:00 +00:00</pubDate>
                <guid isPermaLink="false">234037</guid>
                <description><![CDATA[
Silvermine Capital Leads New and Existing Investor Group in Partnership with GlobalStake to Support Strategic Review of Digital Asset and Biotechnology Businesses
Additional Commitments Expected with the Company Targeting $5M in Total ProceedsNEW YORK--(BUSINESS WIRE)--BNB Plus Corp. (Nasdaq: BNBX) (&quot;BNB Plus&quot; or the &quot;Company&quot;), today announced it has secured initial commitments for $4.1M of convertible preferred stock financing, with additional commitments anticipated to bring total proceed...]]></description>
                </item>
                <item>
                <title>Biocytogen Launches AI-Powered RenSuper™ Platform and Industry-First Fully Automated Antibody Discovery Infrastructure</title>
                <link>https://www.pharmiweb.com/press-release/2026-05-26/biocytogen-launches-ai-powered-rensuper-platform-and-industry-first-fully-automated-antibody-discov-1</link>
                <pubDate>Tue, 26 May 2026 03:00:00 +00:00</pubDate>
                <guid isPermaLink="false">234038</guid>
                <description><![CDATA[BEIJING--(BUSINESS WIRE)--#AIPoweredPlatform--Biocytogen today announced the launch of RenSuper Workstation, a next-generation AI-powered antibody discovery platform providing off-the-shelf access to a large-scale, experimentally validated library of fully human therapeutic antibody sequences, together with the RenSuper High-Throughput Antibody Manufacturing Automation Center, a fully automated infrastructure designed to accelerate antibody validation and production.
Built on Biocytogen’s pro...]]></description>
                </item>
                <item>
                <title>BreezeBio Announces Scientific Advisory Board to Support Next Stage of Precision Genetic Medicine Pipeline Development</title>
                <link>https://www.pharmiweb.com/press-release/2026-05-26/breezebio-announces-scientific-advisory-board-to-support-next-stage-of-precision-genetic-medicine-pi</link>
                <pubDate>Tue, 26 May 2026 03:00:00 +00:00</pubDate>
                <guid isPermaLink="false">234039</guid>
                <description><![CDATA[SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--#NanoGalaxy--BreezeBio, Inc., formerly known as GenEdit, today announced the formation of its Scientific Advisory Board to support the company’s next stage of pipeline and platform development. The inaugural SAB brings together leaders with experience spanning cell-specific delivery, immune modulation, therapeutic development, and clinical translation. Their guidance will support BreezeBio as it advances BRZ-101, its lead program in type 1 diabete...]]></description>
                </item>
                <item>
                <title>Autobahn Therapeutics Announces U.S. FDA Fast Track Designation for Elunetirom, a CNS-Directed Thyroid Hormone Receptor Agonist, for the Adjunctive Treatment of Bipolar Depression</title>
                <link>https://www.pharmiweb.com/press-release/2026-05-26/autobahn-therapeutics-announces-us-fda-fast-track-designation-for-elunetirom-a-cns-directed-thyro</link>
                <pubDate>Tue, 26 May 2026 03:00:00 +00:00</pubDate>
                <guid isPermaLink="false">234040</guid>
                <description><![CDATA[
Elunetirom AMPLIFY-BD Phase 2 trial for the adjunctive treatment of bipolar depression ongoing, with topline data on track for the second quarter of 2026SAN DIEGO--(BUSINESS WIRE)--Autobahn Therapeutics, Inc., a biotechnology company developing restorative treatments for people affected by neuropsychiatric disorders, today announced that the U.S. Food and Drug Administration (FDA) granted Fast Track designation to elunetirom, the Company’s lead candidate, for the adjunctive treatment of depr...]]></description>
                </item>
                <item>
                <title>DePuy Synthes Enters Exclusive U.S., Canada and Australia Distribution Agreement for CGBIO’s NOVOSIS</title>
                <link>https://www.pharmiweb.com/press-release/2026-05-26/depuy-synthes-enters-exclusive-us-canada-and-australia-distribution-agreement-for-cgbio-s-novosis</link>
                <pubDate>Tue, 26 May 2026 03:00:00 +00:00</pubDate>
                <guid isPermaLink="false">234041</guid>
                <description><![CDATA[
Partnership strengthens DePuy Synthes’ portfolio with a differentiated bone graft substitute containing growth factors to address unmet need across orthopaedic specialtiesRAYNHAM, Mass.--(BUSINESS WIRE)--DePuy Synthes, a global leader in orthopaedic technologies and solutions, today announced an exclusive distribution agreement1 with CGBIO, a biotechnology company specializing in regenerative medicine, for the development and commercialization of NOVOSIS, an advanced bone graft substitute co...]]></description>
                </item>
                <item>
                <title>Verastem Oncology Appoints Michael P. Bailey to its Board of Directors</title>
                <link>https://www.pharmiweb.com/press-release/2026-05-26/verastem-oncology-appoints-michael-p-bailey-to-its-board-of-directors</link>
                <pubDate>Tue, 26 May 2026 02:30:00 +00:00</pubDate>
                <guid isPermaLink="false">234014</guid>
                <description><![CDATA[BOSTON--(BUSINESS WIRE)--Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with RAS/MAPK pathway-driven cancers, today announced the appointment of Michael P. Bailey to its Board of Directors. The Company also announced that Robert Gagnon stepped down from the Board following the end of his term on May 21, 2026.
“We are excited to have Michael join our Board as he brings more than three decades of experience leading global pharmace...]]></description>
                </item>
                <item>
                <title>Medical Care Technologies Executes (OTC PINK:MDCE) Executes on Approximately $250,000 in Non-Dilutive Capital Generated Through Subsidiary Operations</title>
                <link>https://www.pharmiweb.com/press-release/2026-05-26/medical-care-technologies-executes-otc-pinkmdce-executes-on-approximately-250-000-in-non-dilutiv</link>
                <pubDate>Tue, 26 May 2026 09:11:00 +00:00</pubDate>
                <guid isPermaLink="false">234044</guid>
                <description><![CDATA[Company prioritizes internal capital generation initiatives to support AI development, commercialization, and operational growth MESA, AZ / ACCESS Newswire / May 26, 2026 / Medical Care Technologies, Inc. (OTC Pink:MDCE) (&quot;MDCE&quot; or the &quot;Company&quot;), a technology-focused company advancing AI-driven consumer and enterprise platforms, today announced that it has generated approximately $250,000 in non-dilutive capital through subsidiary asset sales and related operating activities.  The proceeds w...]]></description>
                </item>
                <item>
                <title>DrSkin Named Best Plastic Surgery, Med Spa, and Skin Care Practice in Gilbert</title>
                <link>https://www.pharmiweb.com/press-release/2026-05-26/drskin-named-best-plastic-surgery-med-spa-and-skin-care-practice-in-gilbert</link>
                <pubDate>Tue, 26 May 2026 10:00:00 +00:00</pubDate>
                <guid isPermaLink="false">234043</guid>
                <description><![CDATA[The award recognizes DrSkin&#39;s leadership in plastic surgery, med spa services, and advanced skin care treatments throughout Gilbert and Phoenix. GILBERT, AZ / ACCESS Newswire / May 26, 2026 / DrSkin Plastic Surgery, Regenerative &amp;amp; Medical Spa has been named the 1st Place winner in Plastic Surgery, Med Spa, and Skin Care in the Best of Gilbert 2026 awards. The recognition highlights DrSkin&#39;s growing reputation for surgical excellence, advanced aesthetic medicine, and patient-centered care...]]></description>
                </item>
                <item>
                <title>NeoGenomics to Present New Research at ASCO Annual Meeting 2026</title>
                <link>https://www.pharmiweb.com/press-release/2026-05-26/neogenomics-to-present-new-research-at-asco-annual-meeting-2026</link>
                <pubDate>Tue, 26 May 2026 02:05:00 +00:00</pubDate>
                <guid isPermaLink="false">234015</guid>
                <description><![CDATA[
Presentations highlight advances in MRD, precision oncology, and real-world evidence across solid tumors and hematologic malignanciesFORT MYERS, Fla.--(BUSINESS WIRE)--NeoGenomics, Inc. (NASDAQ: NEO), a leading provider of oncology diagnostic solutions that enable precision medicine, today announced it will showcase eight scientific abstracts at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting, May 29–June 2, 2026, in Chicago (booth #32130).
The abstracts demonstrate NeoG...]]></description>
                </item>
                <item>
                <title>SAGA Diagnostics Announces NeoCircle Publication Demonstrating the Prognostic Value of ctDNA Dynamics in Early Breast Cancer</title>
                <link>https://www.pharmiweb.com/press-release/2026-05-26/saga-diagnostics-announces-neocircle-publication-demonstrating-the-prognostic-value-of-ctdna-dynamic</link>
                <pubDate>Tue, 26 May 2026 02:00:00 +00:00</pubDate>
                <guid isPermaLink="false">234016</guid>
                <description><![CDATA[
NeoCircle study, published in the journal EMBO Molecular Medicine, shows that Pathlight™ detects relapse up to four years ahead of clinical progression and outperforms pathologic complete response as a prognostic markerMORRISVILLE, N.C.--(BUSINESS WIRE)--#BreastCancer--SAGA Diagnostics, a pioneer in tumor-informed blood-based cancer detection and precision medicine redefining the standard for ultrasensitive and early molecular residual disease (MRD) detection, today announced the publication...]]></description>
                </item>
                <item>
                <title>BioTools Innovator 2026 Cohort Includes Top 30 Life Science Tools and Diagnostics Companies</title>
                <link>https://www.pharmiweb.com/press-release/2026-05-26/biotools-innovator-2026-cohort-includes-top-30-life-science-tools-and-diagnostics-companies</link>
                <pubDate>Tue, 26 May 2026 02:00:00 +00:00</pubDate>
                <guid isPermaLink="false">234017</guid>
                <description><![CDATA[
—Tailored mentorship to help startups compete for $300,000 in funding—LOS ANGELES--(BUSINESS WIRE)--#accelerator--BioTools Innovator (BTI), the first accelerator focused exclusively on life science tools and diagnostics startups, has selected 30 companies for its 2026 Accelerator program. These startups will participate in a four-month program offering in-depth, personalized mentorship from senior industry leaders, access to funding opportunities, and meaningful engagement with peers and exp...]]></description>
                </item>
                <item>
                <title>Independent Pharmaceutical Partners with RxERP to Complete Full ERP Transition Through New Hub Platform</title>
                <link>https://www.pharmiweb.com/press-release/2026-05-26/independent-pharmaceutical-partners-with-rxerp-to-complete-full-erp-transition-through-new-hub-platf</link>
                <pubDate>Tue, 26 May 2026 02:00:00 +00:00</pubDate>
                <guid isPermaLink="false">234018</guid>
                <description><![CDATA[
The partnership strengthens Independent Pharmaceutical&#39;s serialization, DSCSA compliance, reporting, and operational infrastructure as the company continues expanding in Rx and OTC distribution.SALT LAKE CITY &amp;amp; WEST CHESTER, Ohio--(BUSINESS WIRE)--#DSCSA--RxERP, a leading provider of pharmaceutical supply chain infrastructure, and Independent Pharmaceutical LLC, a wholesale pharmaceutical distributor, announced today that they have partnered to fully transition Independent Pharmaceutical...]]></description>
                </item>
                <item>
                <title>VoxCell BioInnovation and adMare BioInnovations Partner to Advance Novel Antibody Therapies in a Human-Relevant Vascularized Tissue Platform</title>
                <link>https://www.pharmiweb.com/press-release/2026-05-26/voxcell-bioinnovation-and-admare-bioinnovations-partner-to-advance-novel-antibody-therapies-in-a-human-relevant-vascularized-tissue-platform</link>
                <pubDate>Tue, 26 May 2026 09:44:50 +00:00</pubDate>
                <guid isPermaLink="false">234008</guid>
                <description><![CDATA[VoxCell BioInnovation and adMare BioInnovations Partner to Advance Novel Antibody Therapies in a Human-Relevant Vascularized Tissue Platform
 
Collaboration applies perfusable, immune-competent 3D bioprinted cancer tissue models to preclinical evaluation of next-generation oncology biologics, supporting the FDA’s push toward more predictive, human-relevant testing and reduced reliance on animal models.
 
Victoria, BC and Vancouver, BC, May 13, 2026. VoxCell BioInnovation Inc. (“VoxCell”), a d...]]></description>
                </item>
                <item>
                <title>Kaname Capital Calls on Cawachi Shareholders to Remove President Kawachi Shinji and Outside Director Watanabe Rinji at June AGM</title>
                <link>https://www.pharmiweb.com/press-release/2026-05-26/kaname-capital-calls-on-cawachi-shareholders-to-remove-president-kawachi-shinji-and-outside-director</link>
                <pubDate>Tue, 26 May 2026 01:33:00 +00:00</pubDate>
                <guid isPermaLink="false">234019</guid>
                <description><![CDATA[
A founder built a sector leader. His adopted son-in-law took the family name — but not the business acumen — and has spent twenty-four years presiding over its decline. Nineteen consecutive years of PBR below 1.0&#215;. &#165;24 billion of public shareholder value destroyed. &#165;15.8 billion extracted by Shinji Kawachi to the founding family. If Cawachi cannot be better operated by present management, then it must be better owned — through a trade sale or privatization.
The full white paper is available...]]></description>
                </item>
                <item>
                <title>Compass Pathways to Participate in Jefferies Global Healthcare Conference on June 3, 2026</title>
                <link>https://www.pharmiweb.com/press-release/2026-05-26/compass-pathways-to-participate-in-jefferies-global-healthcare-conference-on-june-3-2026</link>
                <pubDate>Tue, 26 May 2026 01:30:00 +00:00</pubDate>
                <guid isPermaLink="false">234020</guid>
                <description><![CDATA[LONDON &amp;amp; NEW YORK--(BUSINESS WIRE)--$CMPS #Biotech--Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health, announced today that management will attend the Jefferies Global Healthcare Conference on June 3, 2026 and will participate in a fireside chat at 12:45pm ET.
A live audio webcast of this event will be accessible from the “Events” page of the Investors section of the Compass website. A replay...]]></description>
                </item>
                <item>
                <title>From Ambrx to Oncolytics: Why Jared Kelly Believes the Market May Be Missing the Bigger Oncology Story</title>
                <link>https://www.pharmiweb.com/press-release/2026-05-26/from-ambrx-to-oncolytics-why-jared-kelly-believes-the-market-may-be-missing-the-bigger-oncology-sto</link>
                <pubDate>Tue, 26 May 2026 09:00:00 +00:00</pubDate>
                <guid isPermaLink="false">234027</guid>
                <description><![CDATA[SAN DIEGO, CA / ACCESS Newswire / May 26, 2026 / Biotech investors spend enormous amounts of time searching for &quot;the next big thing.&quot; Most never stop to ask a more important question:What does sophisticated pharmaceutical money actually look for before billions of dollars start moving?That distinction matters.Because the biotechnology graveyard is filled with companies that had interesting science but never figured out how to position themselves strategically inside the larger oncology ecosys...]]></description>
                </item>
                <item>
                <title>Wellgistics Health Completes Reverse Split</title>
                <link>https://www.pharmiweb.com/press-release/2026-05-26/wellgistics-health-completes-reverse-split</link>
                <pubDate>Tue, 26 May 2026 08:00:00 +00:00</pubDate>
                <guid isPermaLink="false">234026</guid>
                <description><![CDATA[1-for-50 reverse split of common shares outstanding now complete2,513,425 common shares now outstandingA new CUSIP was issued in connection with reverse split TAMPA, FL / ACCESS Newswire / May 26, 2026 / Wellgistics Health, Inc. (&quot;Wellgistics&quot;) (NASDAQ:WGRX), a Health IT leader, integrating pharmacy dispensing AI platform EinsteinRx™ into patented pharmacy smart contracts platform PharmacyChain™, today announced that it completed a 1-for-50 reverse stock split (the &quot;Reverse Split&quot;) of the Com...]]></description>
                </item>
                <item>
                <title>In the Ebola Emergency, NV-387 is Ready to be Shipped to DRC, and It Compares Favorably as a Treatment for Ebola Versus Possible Options, Says NanoViricides</title>
                <link>https://www.pharmiweb.com/press-release/2026-05-26/in-the-ebola-emergency-nv-387-is-ready-to-be-shipped-to-drc-and-it-compares-favorably-as-a-treatme</link>
                <pubDate>Tue, 26 May 2026 08:30:00 +00:00</pubDate>
                <guid isPermaLink="false">234025</guid>
                <description><![CDATA[SHELTON, CT / ACCESS Newswire / May 26, 2026 / NanoViricides, Inc. (NYSE American:NNVC) (the &quot;Company&quot;), a clinical stage leader developing antiviral drugs that viruses cannot escape, compares potential treatment options for Ebola Bundibugyo virus strain and finds that the Company&#39;s broad-spectrum antiviral drug candidate NV-387 is worthy of evaluation in this scenario.The rare Bundibugyo strain of Ebola virus causing the current outbreak appears to be its new variant, likely freshly introduc...]]></description>
                </item>
                <item>
                <title>Aspira Women&#39;s Health and Cleveland Clinic Expand Strategic Collaboration to Advance AI-Powered Diagnostics in Women&#39;s Health</title>
                <link>https://www.pharmiweb.com/press-release/2026-05-26/aspira-womens-health-and-cleveland-clinic-expand-strategic-collaboration-to-advance-ai-powered-diag</link>
                <pubDate>Tue, 26 May 2026 09:02:00 +00:00</pubDate>
                <guid isPermaLink="false">234024</guid>
                <description><![CDATA[Collaboration aims to accelerate biomarker discovery, strengthen translational research capabilities, and support scalable clinical validation AUSTIN, TX AND CLEVELAND, OH / ACCESS Newswire / May 26, 2026 / Aspira Women&#39;s Health Inc. (OTCQX:AWHL) (&quot;Aspira&quot; or the &quot;Company&quot;), a bio-analytical company focused on the development of AI-powered, noninvasive diagnostics for women&#39;s health, and Cleveland Clinic have signed an agreement to improve women&#39;s health diagnostics.Under the terms of this Ma...]]></description>
                </item>
                <item>
                <title>First Trust Global Funds PLC UK Regulatory Announcement: Net Asset Value(s)</title>
                <link>https://www.pharmiweb.com/press-release/2026-05-26/first-trust-global-funds-plc-uk-regulatory-announcement-net-asset-value-s-1</link>
                <pubDate>Tue, 26 May 2026 12:59:00 +00:00</pubDate>
                <guid isPermaLink="false">234009</guid>
                <description><![CDATA[LONDON--(BUSINESS WIRE)-- 

Funds

Date
TIDM
ISIN Code
Shares in Issue
Currency
Net Asset Value
NAV/per Share


First Trust NYSE Arca Biotechnology UCITS ETF
25.05.2026
FBTU.LN
IE00BL0L0H60
475,002.00
USD
12,395,547.42
26.096

  Contacts 
First Trust Global Funds PLC]]></description>
                </item>
                <item>
                <title>Croma Skincare – Where Science Meets Skin</title>
                <link>https://www.pharmiweb.com/press-release/2026-05-26/croma-skincare-where-science-meets-skin</link>
                <pubDate>Tue, 26 May 2026 12:43:00 +00:00</pubDate>
                <guid isPermaLink="false">234010</guid>
                <description><![CDATA[LEOBENDORF, Austria--(BUSINESS WIRE)--#cromapharma--With Croma Skincare, Austrian family-owned company Croma Pharma translates decades of expertise in aesthetic medicine into a modern skincare line designed for everyday results. Rather than following short-lived trends, Croma focuses on scientifically proven ingredients and pharmaceutical-grade formulations that deliver visible performance while fitting seamlessly into daily routines.
Building on 50 years of experience in hyaluronic acid, Cro...]]></description>
                </item>
                <item>
                <title>Tecan Establishes Direct Sales and Specialist Lab Automation Service Operations in India</title>
                <link>https://www.pharmiweb.com/press-release/2026-05-26/tecan-establishes-direct-sales-and-specialist-lab-automation-service-operations-in-india</link>
                <pubDate>Tue, 26 May 2026 12:43:00 +00:00</pubDate>
                <guid isPermaLink="false">234011</guid>
                <description><![CDATA[
Strengthening local presence and customer support in a high-growth life sciences marketM&#196;NNEDORF, Switzerland--(BUSINESS WIRE)--Tecan (SIX Swiss Exchange: TECN), a global provider of laboratory automation and solutions, today announced the launch of direct operations in India, including a dedicated local sales and service team based in Gurugram, near New Delhi. The launch, marked with a ribbon-cutting ceremony, is an important milestone in the company’s geographical expansion and reinforces...]]></description>
                </item>
                <item>
                <title>Yunu Launches De-ID &amp; Export to Simplify Site-to-Sponsor Trial Data Sharing </title>
                <link>https://www.pharmiweb.com/press-release/2026-05-26/yunu-launches-de-id-export-to-simplify-site-to-sponsor-trial-data-sharing</link>
                <pubDate>Tue, 26 May 2026 07:00:00 +00:00</pubDate>
                <guid isPermaLink="false">234021</guid>
                <description><![CDATA[New Capabilities Help Sites Anonymize and Export Trial Images and Results With Greater Control, Stronger Traceability, and Less Manual Effort   CARY, NC / ACCESS Newswire / May 26, 2026 / Yunu today announced De-ID &amp;amp; Export, a new add-on capability designed to give sites a streamlined way to anonymize and export trial images and results directly from their existing workflow.For many research teams, retrieving and sharing trial data still depends on inefficient PACS retrieval workflows, di...]]></description>
                </item>
                <item>
                <title>RapidClaims Earns Second Consecutive Black Book AI Claims Automation Distinction</title>
                <link>https://www.pharmiweb.com/press-release/2026-05-26/rapidclaims-earns-second-consecutive-black-book-ai-claims-automation-distinction</link>
                <pubDate>Tue, 26 May 2026 07:00:00 +00:00</pubDate>
                <guid isPermaLink="false">234013</guid>
                <description><![CDATA[Black Book&#39;s 2026 report finds AI-powered claims automation entering a new phase of maturity as physician practices prioritize denial prevention, reimbursement speed, API readiness, compliance, and measurable ROI NEW YORK CITY, NY / ACCESS Newswire / May 26, 2026 / Black Book Market Research today released findings from its 2026 comparative performance report on AI-Powered Claims Automation for Physician Practices &amp;amp; Groups, showing that the market is shifting from rules-based claim edits...]]></description>
                </item>
                <item>
                <title>Merz Therapeutics and Kvvit Enter Exclusive Agreement for INBRIJA&#174; (levodopa inhalation powder) in Mainland China, Hong Kong and Macao</title>
                <link>https://www.pharmiweb.com/press-release/2026-05-26/merz-therapeutics-and-kvvit-enter-exclusive-agreement-for-inbrija-levodopa-inhalation-powder-in-m</link>
                <pubDate>Tue, 26 May 2026 10:00:00 +00:00</pubDate>
                <guid isPermaLink="false">234003</guid>
                <description><![CDATA[

Kvvit to lead local development, regulatory activities and commercialization of INBRIJA&#174; in mainland China, Hong Kong and Macao​

Under the agreement, Merz Therapeutics will receive upfront, development and commercial milestone payments, and tiered supply and royalty arrangements, with no manufacturing rights granted to Kvvit​
FRANKFURT, Germany &amp;amp; GANZHOU, China--(BUSINESS WIRE)--Merz Therapeutics GmbH and Jiangxi Kvvit Pharmaceutical Co. Ltd. today announced that the companies have ent...]]></description>
                </item>
                <item>
                <title>Bial Announces Completion of Phase 2b ACTIVATE Study with BIA 28-6156 in GBA1-Associated Parkinson’s</title>
                <link>https://www.pharmiweb.com/press-release/2026-05-26/bial-announces-completion-of-phase-2b-activate-study-with-bia-28-6156-in-gba1-associated-parkinson-s</link>
                <pubDate>Tue, 26 May 2026 09:00:00 +00:00</pubDate>
                <guid isPermaLink="false">234004</guid>
                <description><![CDATA[

Study Topline results will be released around the end of Q2 2026

BIA 28-6156 is being developed as a potential first-in-class disease-modifying therapy in GBA-PD

Bial was present at the GBA1 conference and is currently attending the World Parkinson Congress
PORTO, Portugal--(BUSINESS WIRE)--#BIA28--Bial, an innovation-driven biopharmaceutical company focused on neurosciences and rare diseases, today announced the completion of the treatment period in its Phase 2b ACTIVATE study of BIA 28-...]]></description>
                </item>
                <item>
                <title>First Trust Global Funds PLC UK Regulatory Announcement: Net Asset Value(s)</title>
                <link>https://www.pharmiweb.com/press-release/2026-05-26/first-trust-global-funds-plc-uk-regulatory-announcement-net-asset-value-s</link>
                <pubDate>Tue, 26 May 2026 09:00:00 +00:00</pubDate>
                <guid isPermaLink="false">234005</guid>
                <description><![CDATA[LONDON--(BUSINESS WIRE)-- 

Funds

Date
TIDM
ISIN Code
Shares in Issue
Currency
Net Asset Value
NAV/per Share


First Trust NYSE Arca Biotechnology UCITS ETF
22.05.2026
FBTU.LN
IE00BL0L0H60
475,002.00
USD
12,395,751.19
26.096

  Contacts 
First Trust Global Funds PLC]]></description>
                </item>
                <item>
                <title>Biovica Receives Expanded Work Order from Clinical-Stage Oncology Company for Next-Generation CDK Inhibitor Program</title>
                <link>https://www.pharmiweb.com/press-release/2026-05-26/biovica-receives-expanded-work-order-from-clinical-stage-oncology-company-for-next-generation-cdk-in</link>
                <pubDate>Tue, 26 May 2026 03:05:00 +00:00</pubDate>
                <guid isPermaLink="false">234002</guid>
                <description><![CDATA[UPPSALA, SE / ACCESS Newswire / May 26, 2026 / Biovica International (STO:BIOVIC-B)(STO:BIOVIC.B)(FRA:9II) - Biovica, active in blood-based cancer monitoring, today announced an expansion of an existing Pharma Services work order from a clinical-stage biopharmaceutical company developing a next-generation CDK inhibitor for solid tumors. The expanded work order amounts to approximately USD 75,000 (SEK 700,000).The company has previously engaged Biovica in multiple projects related to its leadi...]]></description>
                </item>
                <item>
                <title>Peanut Allergy Treatment Market Set for Significant Growth by 2031, Driven by Emerging Targeted Therapies and Rising Disease Awareness</title>
                <link>https://www.pharmiweb.com/press-release/2026-05-25/peanut-allergy-treatment-market-set-for-significant-growth-by-2031-driven-by-emerging-targeted-therapies-and-rising-disease-awareness</link>
                <pubDate>Mon, 25 May 2026 07:09:41 +00:00</pubDate>
                <guid isPermaLink="false">233965</guid>
                <description><![CDATA[Peanut Allergy Treatment Market Overview:
The global Peanut Allergy Treatment Market is projected to grow at a CAGR of around 12% over the next five years. Rising prevalence of peanut allergies worldwide, increasing rates of clinical diagnosis, growing acceptance of immunotherapy-based interventions, favorable regulatory approvals for standardized therapies, and heightened awareness among caregivers and healthcare professionals are major factors supporting market expansion. In addition, the i...]]></description>
                </item>
                <item>
                <title>Pulse Oximeter Market by Application, Type, Component, and Geography - Global Industry Outlook and Forecast 2025-2030</title>
                <link>https://www.pharmiweb.com/press-release/2026-05-25/pulse-oximeter-market-by-application-type-component-and-geography-global-industry-outlook-and-forecast-2025-2030</link>
                <pubDate>Mon, 25 May 2026 06:49:30 +00:00</pubDate>
                <guid isPermaLink="false">233963</guid>
                <description><![CDATA[Pulse Oximeter Market Overview:
The global pulse oximeter market is expected to expand at a compound annual growth rate (CAGR) of approximately 7% over the forecast period. Market growth is primarily driven by the rising incidence of respiratory disorders such as chronic obstructive pulmonary disease (COPD) and asthma, increasing adoption of remote patient monitoring solutions, expansion of wearable and connected healthcare technologies, and a growing geriatric population with chronic health...]]></description>
                </item>
                <item>
                <title>Single-use Assemblies Market Growth - Market Analysis, Size, Share, Trends, Demand, Overview and Segment Forecast To 2031</title>
                <link>https://www.pharmiweb.com/press-release/2026-05-25/single-use-assemblies-market-growth-market-analysis-size-share-trends-demand-overview-and-segment-forecast-to-2031</link>
                <pubDate>Mon, 25 May 2026 05:56:16 +00:00</pubDate>
                <guid isPermaLink="false">233953</guid>
                <description><![CDATA[Single-Use Assemblies Market Accelerating the Future of Flexible Bioprocessing
The global single-use assemblies market is witnessing remarkable expansion as the biopharmaceutical industry increasingly transitions toward flexible, scalable, and contamination-resistant manufacturing systems. Growing production of biologics, vaccines, biosimilars, and advanced therapies has significantly increased the need for sterile and efficient fluid-handling solutions that can support complex production wor...]]></description>
                </item>
                <item>
                <title>High Potency API CDMOs Market Share Leaders, Market Analysis, Developments and Regional Forecast 2031</title>
                <link>https://www.pharmiweb.com/press-release/2026-05-25/high-potency-api-cdmos-market-share-leaders-market-analysis-developments-and-regional-forecast-2031</link>
                <pubDate>Mon, 25 May 2026 06:04:25 +00:00</pubDate>
                <guid isPermaLink="false">233955</guid>
                <description><![CDATA[Global High Potency API CDMOs Market OverviewThe global high potency active pharmaceutical ingredient (HPAPI) CDMOs market is anticipated to witness strong single-digit growth through 2031, supported by the rising demand for oncology therapeutics and the increasing adoption of targeted treatment approaches. The growing pipeline of small-molecule highly potent drugs in various stages of development is significantly contributing to market expansion. Additionally, pharmaceutical companies are in...]]></description>
                </item>
                <item>
                <title>MetrioPharm AG: Prof. Dr. med. J&#252;rgen Braun Appointed as New Member of the Scientific Advisory Board</title>
                <link>https://www.pharmiweb.com/press-release/2026-05-26/metriopharm-ag-prof-dr-med-juergen-braun-appointed-as-new-member-of-the-scientific-advisory-board</link>
                <pubDate>Tue, 26 May 2026 07:14:09 +00:00</pubDate>
                <guid isPermaLink="false">233995</guid>
                <description><![CDATA[
Prof. Dr. med. J&#252;rgen Braun joins the Scientific Advisory Board of MetrioPharm AG.
With more than 800 peer-reviewed publications and various prestigious awards, Prof. Braun is internationally recognized as a leading expert in the field of modern clinical and academic rheumatology.

Zurich, May 26, 2026 – MetrioPharm AG, a clinical-stage biotechnology company developing medicines for inflammatory and infectious diseases, today announced that Prof. Dr. med. J&#252;rgen Braun is joining the company’...]]></description>
                </item>
                <item>
                <title>AI in Pathology Market Executive Summary, Segmentation, Review, Trends, Opportunities, Growth, Demand and Forecast to 2031</title>
                <link>https://www.pharmiweb.com/press-release/2026-05-26/ai-in-pathology-market-executive-summary-segmentation-review-trends-opportunities-growth-demand-and-forecast-to-2031</link>
                <pubDate>Tue, 26 May 2026 05:08:27 +00:00</pubDate>
                <guid isPermaLink="false">233979</guid>
                <description><![CDATA[AI in Pathology Market OverviewThe global AI in pathology market is undergoing rapid expansion, driven by transformative changes across diagnostic medicine and healthcare technology. The market is expected to grow at a strong compound annual growth rate of approximately 26% during the forecast period, reflecting the accelerating adoption of artificial intelligence across clinical and research settings. This growth is largely supported by the increasing need for early and precise disease detec...]]></description>
                </item>
                <item>
                <title>Laboratory Equipment Market Depth Study, Analysis, Key Drivers, Top Players, Trends and Forecast 2030</title>
                <link>https://www.pharmiweb.com/press-release/2026-05-26/laboratory-equipment-market-depth-study-analysis-key-drivers-top-players-trends-and-forecast-2030</link>
                <pubDate>Tue, 26 May 2026 06:21:39 +00:00</pubDate>
                <guid isPermaLink="false">233986</guid>
                <description><![CDATA[Market OutlookThe global laboratory equipment market is projected to register a robust compound annual growth rate of approximately 8% during the forecast period, supported by rapid technological progress and expanding research activities across multiple scientific domains. Increasing adoption of automation, artificial intelligence, and digitally enabled laboratory solutions is transforming traditional lab environments into highly efficient and data-driven ecosystems. Rising investments in li...]]></description>
                </item>
                <item>
                <title>Wearable Medical Devices Market: Global Market Growth Study, Future Trends, Demands, and Top Players Data by Forecast to 2031</title>
                <link>https://www.pharmiweb.com/press-release/2026-05-26/wearable-medical-devices-market-global-market-growth-study-future-trends-demands-and-top-players-data-by-forecast-to-2031</link>
                <pubDate>Tue, 26 May 2026 06:14:06 +00:00</pubDate>
                <guid isPermaLink="false">233985</guid>
                <description><![CDATA[Global Wearable Medical Devices Market OverviewThe global wearable medical devices market is expected to witness robust growth during the forecast period, registering an estimated compound annual growth rate of around 25%. This strong expansion is primarily driven by the increasing burden of chronic diseases such as diabetes, cardiovascular disorders, and neurological conditions. The growing acceptance of wearable technologies among consumers, rising demand for remote patient monitoring, expa...]]></description>
                </item>
                <item>
                <title>Spatial Biology Market 2025-2030 | Analysis, Forecast, Size, Share, Growth, Trends and Insight</title>
                <link>https://www.pharmiweb.com/press-release/2026-05-26/spatial-biology-market-2025-2030-analysis-forecast-size-share-growth-trends-and-insight</link>
                <pubDate>Tue, 26 May 2026 06:12:14 +00:00</pubDate>
                <guid isPermaLink="false">233981</guid>
                <description><![CDATA[Spatial Biology Market Overview:
 
The global spatial biology market is projected to grow at a compound annual growth rate (CAGR) of approximately 15% over the next five years. Key factors fueling this growth include the rising incidence of cancer, technological advancements, increased investments in life sciences and personalized medicine, the development of more accessible and flexible platforms, and the expansion of single-cell omics.
 
Download Sample PDF Copy: https://meditechin,sights.c...]]></description>
                </item>
                <item>
                <title>Artificial Intelligence in Drug Discovery Market Research, Size, Share, Trends, Demand &amp; Growth Analysis by 2029</title>
                <link>https://www.pharmiweb.com/press-release/2026-05-26/artificial-intelligence-in-drug-discovery-market-research-size-share-trends-demand-growth-analysis-by-2029</link>
                <pubDate>Tue, 26 May 2026 06:33:20 +00:00</pubDate>
                <guid isPermaLink="false">233990</guid>
                <description><![CDATA[Artificial Intelligence (AI) in Drug Discovery Market Overview:
The global Artificial Intelligence (AI) in drug discovery market is projected to grow at a rate of 25-30% over the next five years. Key factors driving this growth include the increasing need to lower drug development costs and timelines, the rising adoption of AI technologies within the healthcare and life sciences sectors, the growing volume of data generated in life sciences, advancements in computing power, and the expanding...]]></description>
                </item>
                <item>
                <title>In-Vitro Fertilization (IVF) Market Size, Share, Segmentation, Review, Trends, Opportunities, Growth, Demand and Forecast to 2029</title>
                <link>https://www.pharmiweb.com/press-release/2026-05-26/in-vitro-fertilization-ivf-market-size-share-segmentation-review-trends-opportunities-growth-demand-and-forecast-to-2029</link>
                <pubDate>Tue, 26 May 2026 06:24:37 +00:00</pubDate>
                <guid isPermaLink="false">233988</guid>
                <description><![CDATA[In-Vitro Fertilization (IVF) Market Overview:
The global In-Vitro Fertilization (IVF) market is poised to experience robust growth, with an anticipated compound annual growth rate (CAGR) of 9% through 2029. Several factors are driving this upward trajectory, including the increasing average age of first-time mothers, technological innovations in IVF devices, the rise of IVF tourism, a growing number of fertility clinics worldwide, declining fertility rates, rising instances of male infertilit...]]></description>
                </item>
                <item>
                <title>Notice To Annual General Meeting in AlzeCure Pharma AB</title>
                <link>https://www.pharmiweb.com/press-release/2026-05-26/notice-to-annual-general-meeting-in-alzecure-pharma-ab</link>
                <pubDate>Tue, 26 May 2026 02:20:00 +00:00</pubDate>
                <guid isPermaLink="false">233993</guid>
                <description><![CDATA[STOCKHOLM, SE / ACCESS Newswire / May 26, 2026 / AlzeCure Pharma (STO:ALZCUR)(FRA:AC6) - The shareholders of AlzeCure Pharma AB, reg. no. 559094-8302 (the &quot;Company&quot;) are hereby invited to attend the annual general meeting to be held on Monday 29 June 2026 at 4 p.m. CET at Synch Law&#39;s premises at Birger Jarlsgatan 6, in Stockholm.REGISTRATION AND NOTIFICATIONShareholders who wish to attend the annual general meeting shall;i. be recorded in the share register maintained by Euroclear Sweden AB n...]]></description>
                </item>
                <item>
                <title>MindMaze Therapeutics Announces CHF 8.0 Million Strategic Equity Financing</title>
                <link>https://www.pharmiweb.com/press-release/2026-05-26/mindmaze-therapeutics-announces-chf-80-million-strategic-equity-financing</link>
                <pubDate>Tue, 26 May 2026 01:50:00 +00:00</pubDate>
                <guid isPermaLink="false">233992</guid>
                <description><![CDATA[GENEVA, CH / ACCESS Newswire / May 26, 2026 / MindMaze Therapeutics Holding SA (SIX:MMTX) (MindMaze Therapeutics or the Company), a global leader in scalable precision neurotherapeutics, today announced it has entered into a definitive agreement for a CHF 8.0 million equity financing with Neuro.io Group SA (Neuro.io), through which Neuro.io will acquire a strategic equity position in the Company. The proceeds will support the Company&#39;s commercial priorities, including scaling its U.S. footpri...]]></description>
                </item>
                <item>
                <title>Vicore Pharma to Present at the Jefferies Global Healthcare Conference</title>
                <link>https://www.pharmiweb.com/press-release/2026-05-26/vicore-pharma-to-present-at-the-jefferies-global-healthcare-conference</link>
                <pubDate>Tue, 26 May 2026 02:20:00 +00:00</pubDate>
                <guid isPermaLink="false">233991</guid>
                <description><![CDATA[STOCKHOLM, SE / ACCESS Newswire / May 26, 2026 / Vicore Pharma Holding AB (Nasdaq Stockholm:VICO), unlocking the potential of a novel class of drugs, angiotensin II type 2 (AT2) receptor agonists, today announced participation in the Jefferies Global Healthcare Conference:Location: New York, New York Format: Fireside chat and 1&#215;1 meetings Webcast: Link Presentation Date and Time: Thursday June 4th at 2:35 PM Participants: Ahmed Mousa, CEO, and Bernt van den Blink, CMO For more information, pl...]]></description>
                </item>
                <item>
                <title>MMJ International Holdings Rejects &quot;Anti-Marijuana&quot; Label, Defends Science Based Standards for Cannabinoid Medicines</title>
                <link>https://www.pharmiweb.com/press-release/2026-05-25/mmj-international-holdings-rejects-anti-marijuana-label-defends-science-based-standards-for-canna</link>
                <pubDate>Mon, 25 May 2026 02:15:00 +00:00</pubDate>
                <guid isPermaLink="false">233976</guid>
                <description><![CDATA[Clinical-Stage Pharmaceutical Developer Says Recent Coverage Misses the Real Story: Marijuana Chemistry, Safety, and Scientific Validation WASHINGTON, D.C. / ACCESS Newswire / May 25, 2026 / MMJ International Holdings, Inc. (&quot;MMJ&quot;) today responded to recent media coverage surrounding the challenge to the Centers for Medicare &amp;amp; Medicaid Services&#39; (CMS) Substance Access Beneficiary Engagement Incentive (BEI) program, arguing that the ongoing portrayal of the litigation as a &quot;pro-marijuana v...]]></description>
                </item>
                <item>
                <title>Black Book Research Releases State of Digital Healthcare IT 2026: Egypt Market Report</title>
                <link>https://www.pharmiweb.com/press-release/2026-05-25/black-book-research-releases-state-of-digital-healthcare-it-2026-egypt-market-report</link>
                <pubDate>Mon, 25 May 2026 07:25:00 +00:00</pubDate>
                <guid isPermaLink="false">233971</guid>
                <description><![CDATA[New report examines Egypt&#39;s healthcare IT modernization, Universal Health Insurance rollout, digital claims, EHR adoption, pharmacy technology, diagnostics, AI, cybersecurity, and vendor landscape NEW YORK CITY, NY / ACCESS Newswire / May 25, 2026 / Black Book Research has released State of Digital Healthcare IT 2026: Egypt, a new market intelligence report analyzing one of the Middle East and Africa&#39;s most important healthcare IT growth markets as Egypt advances Universal Health Insurance, p...]]></description>
                </item>
    </channel>
</rss>